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ABSTRACT OF DISSERTATION

NONCONTACT DIFFUSE CORRELATION TOMOGRAPHY
OF BREAST TUMOR

Since aggressive cancers are frequently hypermetabolic with angiogenic vessels,
quantification of blood flow (BF) can be vital for cancer diagnosis. Our laboratory has
developed a noncontact diffuse correlation tomography (ncDCT) system for 3-D imaging
of BF distribution in deep tissues (up to centimeters). The ncDCT system employs two
sets of optical lenses to project source and detector fibers respectively onto the tissue
surface, and applies finite element framework to model light transportation in complex
tissue geometries. This thesis reports our first step to adapt the ncDCT system for 3-D
imaging of BF contrasts in human breast tumors. A commercial 3-D camera was used to
obtain breast surface geometry which was then converted to a solid volume mesh. An
ncDCT probe scanned over a region of interest on the breast mesh surface and the
measured boundary data were used for 3-D image reconstruction of BF distribution. This
technique was tested with computer simulations and in 28 patients with breast tumors.
Results from computer simulations suggest that relatively high accuracy can be achieved
when the entire tumor was within the sensitive region of diffuse light. Image
reconstruction with a priori knowledge of the tumor volume and location can
significantly improve the accuracy in recovery of tumor BF contrasts. In vivo ncDCT
imaging results from the majority of breast tumors showed higher BF contrasts in the
tumor regions compared to the surrounding tissues. Reconstructed tumor depths and
dimensions matched ultrasound imaging results when the tumors were within the
sensitive region of light propagation. The results demonstrate that ncDCT system has the
potential to image BF distributions in soft and vulnerable tissues without distorting tissue
hemodynamics. In addition to this primary study, detector fibers with different modes
(i.e., single-mode, few-mode, multimode) for photon collection were experimentally
explored to improve the signal-to-noise ratio of diffuse correlation spectroscopy flowoximeter measurements.
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Diffuse Correlation Spectroscopy/Tomography (DCS/DCT); Breast tumor; Blood flow
contrast; Noncontact; Optical fiber mode
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CHAPTER 1 INTRODUCTION

1.1 Classification of Breast Disease
The main function of the breasts is to make milk for breastfeeding. Glandular tissues
and supporting (stromal) tissues are two main types of tissues in breasts (1). The
glandular part of the breast includes the lobules and ducts (Figure 1.1). In women who
are breastfeeding, the cells of the lobules make milk. The milk then moves through the
ducts, which are tiny tubes that carry milk, to the nipple. Each breast has several ducts
that lead out to the nipple. The support tissue of the breast includes fatty tissue and
fibrous connective tissue that give the breast its size and shape.

Figure 1
Figure 1.1: A schematic representation of the breast (1).
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Changes in the breasts may be caused either by benign conditions or cancer. Most
breast lesions detected are benign, which don’t grow uncontrollably or spread, but they
may be linked to breast cancer risk (2, 3). Benign breast diseases constitute
heterogeneous groups of lesions including developmental abnormalities, inflammatory
lesions, fibrocystic changes, proliferative stromal lesions, and neoplasms (3). Ectopic
breast, which has been described as both supernumerary and aberrant breast tissue, is the
most common congenital abnormality of the breast. Supernumerary breast tissue is seen
mostly along the milk line; the most frequent sites are the chest wall, vulva, and axilla.
However, malignancies in ectopic breasts are very rare (4, 5). Inflammatory and related
lesions include mastitis, mammary duct ectasia and fat necrosis. Among those, mastitis is
often caused by a breast infection and is most often seen in lactating women. Although
mastitis does not raise a women’s risk of developing breast cancer, an uncommon type of
inflammatory breast cancer has symptoms that are a lot like mastitis. Mammary duct
ectasia also called periductal mastitis. The most important histological feature of this
disorder is the dilatation of major ducts in the subareolar region. There is no evidence
indicating it is associated with an increased risk for breast cancer. Fat necrosis of the
breast is a benign nonsuppurative inflammatory process of adipose tissue. Fibrocystic
changes constitute the most frequent benign disorder of the breast. They comprise both
cysts and solid lesions, including adenosis, epithelial hyperplasia with or without atypia,
apocrine metaplasia, radial scar, and papilloma. In order to determine the risk factors for
fibrocystic changes, they are subdivided into nonproliferative lesions, proliferative
lesions without atypia, and proliferative lesions with atypical (atypical hyperplasia) (6-8).
Proliferative stromal lesions include diabetic fibrous mastopathy and pseudoangiomatous

2

stromal hyperplasia of the breast. Neoplasms include fibroadenoma, lipoma, adenoma,
hamartoma and granular cell tumor. Specifically, fibroadenoma is the most common
lesion of the breast and it occurs in 25% of asymptomatic women. The peak incidence of
fibroadenoma is between the ages of 15 and 35 years.
Breast cancer begins in the lobules and ducts (Figure 1.1). According to the extent of
spread, breast cancer can be determined as in situ (noninvasive) or invasive. For in situ
breast cancers, there are abnormal breast changes in the cells lining the breast ducts or
lobules. The noninvasive breast tumors include ductal carcinoma in situ (DCIS), lobular
carcinoma in situ (LCIS), and other in situ breast cancers have characteristics of both
DCIS and LCIS. For invasive breast cancers, the abnormal cells have broken through the
ductal or glandular walls and grown into surrounding breast tissue. Invasive breast
cancers include ductal carcinoma, which is the most common type, invasive lobular
carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma and invasive
papillary carcinoma (9).

1.2 Medical Imaging for Breast Tumor
About 1 in 8 women in the United States will develop invasive breast cancer over her
lifetime. Its high incidence and associated mortality makes it an important public health
problem (2, 10). Finding breast cancers when they remain localized results in 5-year
relative survival rates of 99% (2). The current clinical standard for breast screening is xray mammography which can often identify cancer several years before physical
symptoms develop (2). The significant decrease in breast cancer mortality, which
amounts to nearly 30% since 1990, is due in large part to the earlier detection of breast
3

cancer through mammographic screen (11). However, mammography is hampered by a
significant false-positive rate, which is especially high for women with dense breast
tissue. The dense breast population is a particularly important subset of women because
they experience higher incidence and mortality rates from the disease (12, 13).
Other imaging modalities used as adjunctive screening tools for breast cancers
include x-ray computed tomography (CT), magnetic resonance imaging (MRI), positron
emission tomography (PET) and ultrasonography (14-16). For women with dense breasts,
ultrasound imaging yields an incremental cancer detection rate. However, there are issues
related to high false-positive rates, operator dependency of the examination and inability
to image most DCIS. For women with the highest risk of developing breast cancer,
screening MRI is adopted to provide higher screen sensitivity. However, considerable
cost (i.e., larger than $50,000 per cancer) is added. PET scan can provide physiological
information on the uptake of glucose and its metabolism, both of which are increased in
malignant tissue (17). Combined PET/CT systems are increasingly available, which fuse
PET and CT images to provide combined physiologic and anatomic imaging (18).
However, both PET and CT are not used for primary tumor detection (invasive tumor
with diameter smaller than 1 cm) and they are recommended for detection of metastases
and recurrent disease in breast cancer (17, 18).

1.3 Optical Imaging for Breast Tumor
Optical imaging is currently emerging as a promising new addition to medical
imaging, which provides biologists and clinicians new ways to detect, diagnose and study
disease (19). Optical microscopy imaging with high spatial resolution for cancer research
4

has been paid much attention in the past few decades (20-23). Laser scanning confocal
fluorescence microscopy provides high resolution, depth resolved, 3-D images (24).
Two-photon fluorescence microscopy has later been invented which reduced photo
damage compared with fluorescence confocal microscopy and achieves even higher
spatial resolution and deeper penetration into tissues (20). Optical coherence tomography,
which is analogous to ultrasound, performs high resolution cross-sectional imaging of
tissue scattering (21, 22). While these techniques are all extremely useful, they have a
common limitation. They can only be used to image tissue near the surface. Confocal
microscopy penetrates up to depths of about 50 µm. Two-photon microscopy allows one
to look slightly deeper, up to hundreds of micrometers. OCT goes even deeper, but only
to depths of at most 2-3 mm in highly scattering tissue. The shallow imaging depth
inhibits the use for non-destructive in vivo imaging of breast tumor.
On the other hand, macroscopic imaging allows for larger fields of view and deeper
depths of penetration ranging from millimeters to centimeters. Photoacoustic tomography
(PAT) combines ultrasonic-scale resolution and penetration depth with high sensitivity to
tissue light absorption (25-27). For breast tissue imaging, PAT can visualize vasculature
inside the tissue by virtue of its high hemoglobin content compared to surrounding breast
parenchyma (19, 28-30). However, most currently available PAT systems require the
tissue and ultrasonic detectors to be in contact with a coupling fluid, complicating
experimental procedures. Diffuse correlation spectroscopy (DCS) and near-infrared
spectroscopy (NIRS) have been developed to probe blood flow ， hemoglobin
concentration and oxygen saturation in deep tissue vasculature (several centimeters). A
well-known ‘biological window’ exists in the NIR range (600-900 nm) (Figure 1.2),
5

wherein tissue absorption is relatively low, so that light can penetrate into deep/thick
volumes of tissue (31). For imaging with NIRS/DCS (i.e., diffuse optical/correlation
tomography [DOT/DCT]), multiple points on the tissue boundary are usually illuminated
in a time-sharing fashion and diffuse light patterns are collected around the boundary
using photodetector sets. NIRS/DOT has been used over decades to detect oxygenation
alternations in breast tumors (32-36).

Biological Window

Figure 2
Figure 1.2: Absorption Spectra of Hemoglobin and Water. Tissue absorption coefficients
(µa) shown as a function of wavelength (λ) for oxygenated hemoglobin (HbO2),
deoxygenated hemoglobin (Hb), and water (H2O). Within the NIR spectral window
(~600 – 900 nm), light is able to penetrate deep tissue due to low absorption.

1.4 Diffuse Correlation Spectroscopy (DCS)
DCS is an emerging new technique which provides direct measurement of blood flow
index (BFI) in deep tissues (37-43). DCS takes advantage of the same biological window
6

as traditional NIRS techniques, but employs long-coherence (˃ 5 meter) NIR continuouswave laser as the light source. DCS blood flow measurement is accomplished by
monitoring speckle fluctuations of photons resulting from moving scatterers in biological
tissues. Moving red blood cells (RBCs) inside vessels are primarily responsible for these
fluctuations. In most dynamic experiments, the temporal statistics of light speckle
fluctuations are monitored and the electric field temporal autocorrelation function or its
Fourier transform is quantified. Using a correlation diffusion equation describing the
propagation of electric field temporal autocorrelation function through tissues, the
measured signal is then related to the motion of RBCs and, consequently, BFI is
determined. Relative change in blood flow (rBF) can then be determined by normalizing
BFI to its baseline value (e.g. before physiological change). DCS provides several
attractive new features for blood flow measurement in tissue microvasculature, including
noninvasiveness (i.e., no ionizing radiation, no contrast agents), high temporal resolution
and relatively high penetration depth (up to several centimeters (44)).
DCS technology has been extensively validated in various tissues through
comparisons with laser Doppler flowmetry (45, 46), Doppler ultrasound (47, 48), power
Doppler ultrasound (49, 50), Xenon-CT (51), fluorescent microsphere flow measurement
(52), and arterial spin labeled magnetic resonance imaging (39, 44).
Since measurements of blood flow provide insight about oxygen delivery and the
clearance of metabolic by-products (53), in vivo diffuse optical measurement of blood
flow has been explored for tumor characterization and prediction of treatment outcomes
(54). A few pilot studies of breast tumors using DCS have found increased blood flow
inside the tumor in contrast to surrounding normal tissues (53, 55). Real-time monitoring
7

of breast tumor blood flow response to neoadjuvant chemotherapy also demonstrated the
potential of DCS for assessing cancer therapies (56, 57).

1.5 Current Study Limitations and Thesis Outline
Despite advances in DCS technologies, there have been limited imaging applications
of DCT for tumor detection. An early probe-tissue contact based DCT approach was
applied to tissue phantoms (58), but was disadvantaged in vivo due in part to
compression-induced

hemodynamic

alterations.

A

few

noncontact-based

DCT

examinations have been conducted using the camera lenses positioned between a sample
and optical fibers connected to source and detection elements (59, 60). These
arrangements, however, were only tested on the brain of small animals with limited
probing depth (< 5 mm). Another limitation of these imaging studies was their reliance
on analytical solutions that assumed a simple semi-infinite flat tissue geometry. As such,
there have been no reports of studies using DCT for 3-D imaging of blood flow
distributions in tumors (54).
The focus of my graduate work is to develop a novel noncontact DCT (ncDCT)
system for 3-D imaging of tumor-to-normal blood flow in deep tissues and apply the
system to clinical diagnosis of breast tumors. I have contributed to the development of
DCT theory, to the design and validation of the imaging system (computer simulations
and tissue phantom experiments) and to the clinical applications of diffuse optical
techniques (patients with breast tumors). In addition, I have also explored the use of
different mode fibers for photon collection to improve the signal-to-noise ratio (SNR) of
DCS flow-oximeter measurements. In this thesis, I summarize these technique
8

developments and report our first step to adapt the ncDCT system for 3-D imaging of
blood flow contrasts in human breast tumors.
This thesis is organized into the following chapters. Chapter 2 describes the
theoretical background of NIRS and DCS and the development of DCT for 3-D flow
contrast imaging. Chapter 3 depicts the ncDCT instrumentation, measurement procedures
and initial validation work on tissue-like phantoms under semi-infinite geometry. The
recipes and fabrication procedures for making liquid and solid phantoms are also
included in the appendix. In Chapter 4, further computer simulations are performed to
characterize the performance of ncDCT system for imaging an anomaly (tumor) with
varied flow contrasts and depths inside the tissue volumes with breast-shaped surface
boundaries. Chapter 5 presents in vivo imaging results of blood flow distribution in 28
human breast tumors using ncDCT. Chapter 6 demonstrates the possibility of improving
SNRs of DCS flow-oximeter measurements using single-, few- and multi-mode fibers for
detection. Finally, chapter 7 summarizes the novelties of the present work, my
contributions to the field, study limitations as well as directions for future research.
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CHAPTER 2 DIFFUSE CORRELATION SPECTROSCOPY AND
TOMOGRAPHY: THEORY

2.1 Introduction
In this chapter I provide a theoretical background for the traditional diffuse optical
techniques, including NIRS for tissue optical properties and consequently absolute
oxygenation measurements (Chapter 2.2) and single-wavelength DCS for flow
monitoring (Chapter 2.3). Contributions to further development of DCS/DCT
technologies are then presented including (1) an ncDCT technique for 3-D flow imaging
of deep tissue based on finite element framework (Chapter 2.4.1) and (2) a noise model
for ncDCT for evaluating the influence of measurement noises on image reconstruction
accuracy (Chapter 2.4.2).

2.2 NIRS
The ‘biological window’ in NIR (600-900 nm, see Figure 1.2) has made possible the
application of diffuse optical imaging and spectroscopy in biological tissues. In this
window, the absorption coefficients (𝜇𝑎 ) of water and hemoglobin are low, allowing
photons to travel deeply into tissues (millimeters to centimeters depending on the
wavelength used and tissue optical properties) (61). However, due to the factor that
reduced scattering length (1⁄𝜇𝑠 ′ ≈ 1 𝑚𝑚) is much shorter than the absorption length
(1⁄𝜇𝑎 ≈ 100 𝑚𝑚), scattering events dominate the propagation of photons inside the
tissue. Beyond a few millimeters deep inside tissue, the photons may have been scattered
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multiple times and their directions become random. Thus, the photon propagation in
tissue over a long distance can be treated as a diffusive process (62, 63).
The propagation of photons in highly scattering media such as biological tissues can
be modeled by the diffusion approximation to the radiative transport equation (63, 64).
This diffusion equation, which governs the photon fluence rate, Φ (𝒓, 𝑡) [𝑊𝑎𝑡𝑡 ∙ 𝑐𝑚−2 ]
inside the medium, is written in the frequency domain (FD: using modulated light as the
source) as follows (63, 65):
∇ ∙ (𝐷(𝒓)∇Φ(𝒓, 𝑡)) − 𝜐𝜇𝑎 (𝒓)Φ(𝒓, 𝑡) + 𝜐𝑆(𝒓, 𝑡) =

𝜕Φ(𝒓,𝑡)
𝜕𝑡

(2.1)

Here, 𝒓 is the position vector, t [s] is time and υ [cm ∙ 𝑠 −1 ] is the speed of light in the
medium. 𝜇𝑎 (𝒓) [𝑐𝑚−1] is the absorption coefficient, and 𝐷(𝒓) ≡ 𝑣⁄3(𝜇𝑎 (𝒓) + 𝜇𝑠′ (𝒓)) ≈
𝑣/3µ′𝑠 (𝒓) [𝑐𝑚2 ∙ 𝑠 −1 ] is the photon diffusion coefficient, where 𝜇𝑠′ (𝒓) [𝑐𝑚−1 ] is the
reduced scattering coefficient of the tissue. S(𝒓, 𝑡)[𝑊𝑎𝑡𝑡 ∙ 𝑐𝑚−2 ] is the isotropic source
term which gives the number of photons emitted at position r and time t per unit volume
per unit time. The right hand side of Equation 2.1 shows the change rate of photons
within a sample volume. This rate equals the number of photons scattered into the
volume per unit time from its surroundings, minus the number of photons absorbed per
unit time within the volume, plus the number of photons emitted per unit time from any
sources in the volume (65). This diffusion approximation is valid when 𝜇𝑎 ≪ 𝜇𝑠′ and the
distance between sources and detectors is much greater than the random walk step length
(~ 1 mm in breast tissue).
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For point sources of the form 𝑆(𝒓, 𝑡) = 𝑆0 𝛿(𝒓 − 𝒓𝑠 )exp(−i𝜔t) , where 𝑆0 is a
constant, 𝜔 is the modulation frequency and 𝑟𝑠 is the source location, Equation 2.1
simplifies to (66):
𝐷(𝒓)

𝑖𝜔

𝜐

𝜐

∇ ∙ ((

) ∇Φ(𝒓)) − (𝜇𝑎 (𝒓) +

) Φ(𝒓) = 𝑆0 𝛿(𝒓 − 𝒓𝑠 )

(2.2)

where Φ(𝒓, 𝑡) = Φ(𝒓)exp(−i𝜔t).
To apply the NIR technique for measuring tissue absorption and scattering,
photodetectors were typically used to detect the diffused light at known distances of a
few millimeters to centimeters from point sources. Figure 2.1a shows a simple
measurement setup with one pair of source and detector in reflection geometry. Light
injected into the tissue through a source fiber can be detected by the detector fiber placed
at a distance ρ from another fiber. The sensitive region of diffuse light is usually
described as a “banana pattern” with the penetration depth of ~ρ/2 (65, 67, 68) (see
Figure 2.1a). The analytical solution for Equation 2.2 in this semi-infinite geometry can
be obtained (69):
𝑣𝑆

exp(−𝐾𝑟1 )

Φ(𝜌) = 4𝜋𝐷0 (
where 𝐾 2 = 3𝜇𝑠′ (−

𝑖𝜔
𝑣

𝑟1

−

exp(−𝐾𝑟2 )
𝑟2

)

(2.3)

+ 𝜇𝑎 ) , 𝑟1 = √𝜌2 + 𝑧02 and 𝑟2 = √𝜌2 + (𝑧0 + 2𝑧𝑏 )2 , 𝜌 is the

distance from the source to detector measured along the sample surface, 𝑧𝑏 is the
distance above the tissue surface at which the fluence rate extrapolates to zero and 𝑧0 is
2 1+𝑅

𝑒𝑓𝑓
the effective depth of the source. We use 𝑧0 = 1⁄𝜇𝑠′ and 𝑧𝑏 = 3𝜇′ 1−𝑅 , 𝑅𝑒𝑓𝑓 =
𝑠

𝑒𝑓𝑓

−1.44𝑛−2 + 0.71𝑛−1 + 0.668 + 0.064𝑛, 𝑛 ≈ 1.33(for both tissue and phantom). The
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𝑅𝑒𝑓𝑓 term accounts for the mismatch between the medium and the air indices of
refraction with 𝑛 being the ratio between them.
Multidistance measurements of the phase and the amplitude of the photon fluence rate
Φ(𝒓, 𝑡) with FD system enable to extract optical properties (𝜇𝑠′ and 𝜇𝑎 ) of the measured
medium by fitting the known analytical solution (Equation 2.3) to the measured
boundary data (70-72). In the NIR region, the dominant chromophore in tissue is
hemoglobin (deoxyhemoglobin Hb and oxyhemoglobin HbO2). Since the absorption
spectra of Hb and HbO2 are different (see Figure 1.2) (62), the concentrations of [Hb]
and [HbO2] in biological tissue can be calculated by knowing 𝜇𝑎 at two wavelengths (46,
73). Total hemoglobin concentration (THC) and blood oxygen saturation (StO2) can be
derived based on [Hb] and [HbO2] consequently.
Besides the modulated light used in the FD system, there are other two types of light
sources commonly used in diffuse optics: continuous-wave (CW) and time-resolved (TR)
(see Figures 2.1b-2.1d) (19, 74). The simplest type is CW light where the light intensity
remains constant over time. CW systems enable fast data acquisition and the use of
simple detectors and detection electronics, but cannot determine 𝜇𝑎 and 𝜇𝑠′ simultaneously.
The FD paradigm uses intensity modulated light to illuminate the tissue, and measures
both light intensity attenuation and phase shift at the detector, allowing simultaneously
determination of 𝜇𝑎 and 𝜇𝑠′ . The TR light source delivers short light pulses to the medium,
which are temporally broaden as they propagate through the medium. At the detector, the
detected temporal pulse shape contains the information to determine 𝜇𝑎 and 𝜇𝑠′ . TR
system yields more output than other two modalities but require more complicated
equipment and data analysis.
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Figure 2.1: Sample input and output intensity signals representing the three types of
NIRS techniques. Panel (a) is computer simulated “banana pattern” showing the sampled
volumes in the reflection geometries. Panel (b) shows a CW NIRS, in which attenuated
intensity of continuous illumination is monitored. Panel (c) shows FD NIRS, in which
input light is modulated and the amplitude attenuation and phase shifts are detected.
Panel (d) shows TR NIRS, in which an impulse of light is emitted into the tissue, and the
intensity change with respect to time is detected. Here, I0 and I represent input and
detected intensities, Φ0 represents phase, and M0 represents the frequency of modulation.

2.3 DCS
Similar to CW NIRS, DCS also utilizes NIR light and the same measurement
geometry to probe deep tissue properties. While NIRS employs the static method of
diffuse optical technique to detect slow intensity variations induced by tissue absorption
and scattering, DCS uses the dynamic method to monitor the fast motion of red blood
cells.
When using DCS to detect tissue blood flow, a pair of source and detector fibers is
usually placed along the tissue surface with separation distance of a few millimeters to
centimeters. NIR light generated by a CW long coherent laser (coherence length > 5 m)
emits into tissues through the source fiber. The diffused light transported throughout the
tissue is detected by a single or few-mode fiber connected to a single-photon-counting
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detector. Photons travel inside tissue in a diffusive manner (45, 65), and experience
absorption by tissue absorbers (e.g., hemoglobin and water) and, more often, scattering
by static or dynamic scatterers (e.g., organelles, mitochondria, moving red blood cells)
(see Figure 2.2a). The motions of moving scatterers cause temporal fluctuations in light
intensity, leading to changes in the speckle pattern of interference (38, 41, 54, 58, 65, 67,
75-78). In most dynamic experiments the temporal statistics of light speckle fluctuations
are monitored and the electric field temporal autocorrelation function or its Fourier
transform is quantified. Using a correlation diffusion equation describing the propagation
of electric field temporal autocorrelation function through tissues, the measured signal is
then related to the motion of RBCs and, consequently, blood flow is determined.
The normalized light intensity temporal autocorrelation function is calculated to
characterize these speckle intensity fluctuations at multiple delay time τ:
𝑔2 (𝒓, 𝜏) = 〈𝐼(𝒓, 𝑡) ∙ 𝐼(𝒓, 𝑡 + 𝜏)〉/〈𝐼(𝒓, 𝑡)〉2

(2.4)

Here 𝐼(𝒓, 𝑡) is the detected light intensity at position 𝒓 and time t, and   denotes a
time average (38). Faster intensity fluctuations, which are associated with higher blood
flow, correspond to steeper decay in 𝑔2 (𝒓, 𝜏) curve (Figures 2.2b and 2.2c).
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Figure 2.2: (a) Schematic for multiple scattering along a single photon path in a turbid
media with semi-infinite reflection geometry. Solid green line indicates the photon path
at time t, while the dashed green line represents the photon path at time t+τ. The red and
grey disks indicate blood cell at time t and t+τ, the blood cell is scattered certain distance
during the delay time τ (indicated by blue arrows). (b) Example of detected light intensity
fluctuations from measurements with higher (blue curve) and lower (red curve) blood
flow. (c) Normalized intensity autocorrelation functions 𝑔2 (𝒓, 𝜏) calculated from detected
light intensities in (b). The decay of the intensity autocorrelation function curves is
related to the tissue blood flow.

In order to extract blood flow information from measured 𝑔2 (𝒓, 𝜏) curve, the
normalized electric field temporal autocorrelation function 𝑔1 (𝒓, 𝜏) = 𝐺1 (𝒓, 𝜏)⁄𝐺1 (𝒓, 0),
which contains the information of red blood cell motion, is derived with a correlation
diffusion approach (65). The blood flow index (BFI) is ascertained by fitting the
analytical expression of 𝑔1 (𝒓, 𝜏) to the experimentally measured 𝑔2 (𝒓, 𝜏) using the
Siegert relation (79):
𝑔2 (𝒓, 𝜏) = 1 + 𝛽|𝑔1 (𝒓, 𝜏)|2

(2.5)

Here, 𝛽 = 1⁄𝑁 is a coherence factor depending mainly on the laser coherence and
detection optics, and is inversely proportional to the number of guided modes/speckles (N)
(80). It can be determined experimentally from measured 𝑔2 (𝒓, 𝜏) via 𝛽 = 𝑔2 (𝒓, 𝜏) − 1.
The analytical expression of 𝑔1 (𝒓, 𝜏) is converted from the electric field temporal
autocorrelation function 𝐺1 (𝒓, 𝜏)= 〈𝐸(𝒓, 𝑡) ∙ 𝐸 ∗ (𝒓, 𝑡 + 𝜏)〉. In order to model the
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propagation of 𝐺1 (𝒓, 𝜏) in biological tissues, the correlation diffusion equation in
homogeneous medium for CW light source is developed (38, 58, 81):
𝐷(𝒓)

𝛻 ((

𝑣

1

) 𝛻𝐺1 (𝒓, 𝜏)) − (𝜇𝑎 (𝒓) + 3 𝜇𝑠′ (𝒓)𝑘02 𝛼〈∆𝑟 2 (𝜏)〉) 𝐺1 (𝒓, 𝜏) = −𝑆0 𝛿(𝒓)

(2.6)

where 𝑣 is the light speed in the medium, 𝑆0 𝛿(𝒓) is the CW source term and 𝑆0 is a
constant, 𝑘0 = 2𝜋𝑛⁄𝜆 is the wave number of the incident light, n = 1.33, 𝜆 is the source
light wavelength, and 𝐷(𝒓) ≈ 𝑣/3µ′𝑠 (𝒓) . 〈∆𝑟 2 (𝜏)〉 is the mean square displacement of
the moving scatterers inside the tissue during a time interval τ. A Brownian diffusion
model 〈∆𝑟 2 (𝜏)〉 = 6 𝐷𝐵 (𝒓)𝜏 is often employed with 𝐷𝐵 (𝒓) denoting the effective
diffusion coefficient of the moving scatterers (66, 82). 𝐷𝐵 (𝒓) depends on the exponential
decay rate of the measured correlation functions. An α term (ranging from 0 to 1) is
added to account for the fact that not all scatterers in biological tissues are dynamic, and
α is defined as the ratio of moving (dynamic) scatterers to total (dynamic and static)
scatterers. The combined term, 𝛼𝐷𝐵 (𝒓), is referred to as the blood flow index (BFI) in
tissues and its relative change is commonly used to calculate the relative change of blood
flow (rBF) compared with the baseline BFI before physiological changes. In contrast to
tissue samples, all scatterers in liquid phantom solutions are considered dynamic with
𝛼 ≈ 1, and the flow index is thus reported as simply 𝐷𝐵 (𝒓).
The analytical solution of Equation 2.6 with point source impinging upon a semiinfinite homogeneous medium (Figure 2.2a) is generated as (65):
𝑣𝑆

exp(−𝐾(𝜏)𝑟1 )

𝐺1 (𝜌, 𝜏) = 4𝜋𝐷0 (

𝑟1
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−

exp(−𝐾(𝜏)𝑟2 )
𝑟2

)

(2.7)

2

where 𝐾 2 (𝜏) = 3𝜇𝑠′ 𝜇𝑎 + 𝜇𝑠′ 𝑘02 𝛼〈∆𝑟 2 (𝜏)〉, 𝑟1 , 𝑟2 and 𝜌 are the same as in Equation 2.3.
Consequently, the analytical expression for 𝑔1 (𝒓, 𝜏) is derived as:
exp(−𝐾(𝜏)𝑟1 )

𝑔1 (𝒓, 𝜏) = (

𝑟1

−

exp(−𝐾(𝜏)𝑟2 )

exp(−𝐾(0)𝑟1 )

𝑟2

𝑟1

)⁄(

−

exp(−𝐾(0)𝑟2 )
𝑟2

)

(2.8)

Thus the measurements of 𝑔1 (𝒓, 𝜏) can be fitted the analytical expression based on
Equation 2.8 to yield 𝛼𝐷𝐵 , using given values of ρ and values of 𝜇𝑠′ , 𝜇𝑎 from NIRS
measurements or literature (65, 66, 83).

2.4 Diffuse Correlation Tomography (DCT)
The extension of DCS to DCT is comparable to that of DOS to DOT which models
the propagation of light in diffuse tissue, called “forward problem”, based on Equation
2.1 and solves the “inverse problem” for spatial distribution of optical parameters
(e.g., 𝜇𝑎 and 𝜇𝑠′ ) (60, 84). Similarly, the forward problem for DCT is to calculate the
electric field autocorrelation at the detectors given a geometric model of the optical
parameters, flow index, and source and detector locations and functionality based on
Equation 2.6. The inverse problem for DCT is to recover the flow index distribution
through boundary measurements of autocorrelation function.
Previous studies involving DCT have used perturbation method to derive the forward
problem (58-60), however, this method relies on analytical solution of autocorrelation
function which precludes the transition to complex boundaries and imperfect
heterogeneities. The finite element framework has been applied in DOT as a numerical
approximation of partial differential Equation 2.1 for light propagation model and image
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reconstruction algorithms. This numerical method can resolve the geometry and
heterogeneity limitations for DOS/DOT (85-87). Because of the mathematical similarity
of correlation diffusion equation (Equation 2.6) and photon diffusion equation
(Equation 2.2), the implementation of finite element framework in DCS/DCT has been
developed (37)，adopting software package NIRFAST (for DOT) (87) as a shortcut.
1

Recall Equation 2.6, the term 3 𝜇𝑠′ (𝒓)𝑘02 𝛼⟨∆𝑟 2 (𝜏)⟩ can be reshaped as 𝜇𝑎𝑑 (𝒓, 𝜏) =
2𝜇𝑠′ (𝒓)𝑘02 𝛼𝐷𝐵 (𝒓)𝜏, and is considered as “effective dynamic absorption” due to dynamic
processes on the correlation with 𝜏 (37). DCT is conceptualized as a formulation of DOT
which computes 𝐺1 (𝒓, 𝜏) instead of photon fluence rate Φ(𝒓, 𝑡) , by updating “static
absorption” 𝜇𝑎 (𝒓) to 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) = 𝜇𝑎 (𝒓) + 𝜇𝑎𝑑 (𝒓, 𝜏) , and reconstructing 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏)
instead of 𝜇𝑎 (𝒓) only (37).

2.4.1 Forward and Inverse Models
Chart 1 and Chart 2 illustrate the main commands executed for solving the forward
and inverse problems respectively in DCT using NIRFAST. A homogeneous background
tissue volume mesh with assigned initial optical properties of 𝜇𝑎 (𝒓) and 𝜇𝑠′ (𝒓) is first
generated in the forward solution (see Chart 1). All S-D pairs corresponding to the actual
or simulated scanning of ncDCT probe are placed on the surface of the background mesh.
However, only those with valid links between sources and detectors are configured as
effective pairs for image reconstruction. For simulations, an anomaly region (mimicking
a tumor) inside the background volume mesh is defined and assigned a BFI contrast
relative to the surrounding background. Based on the designed distributions of BFIs,
𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) is updated for each voxel inside the entire tissue volume within a certain
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range of 𝜏. The autocorrelation functions 𝐺1 (𝒓, 𝜏) for multiple τ values from all effective
S-D pairs are then calculated by running the forward model. The boundary BFI data at all
effective S-D pairs are then extracted by fitting 𝐺1 (𝒓, 𝜏) to the analytical expression of
Equation 2.7 under semi-infinite homogeneous geometry.

Generate a homogeneous mesh and
assign 𝜇𝑎 𝒓 and 𝜇𝑠 ′ 𝒓

Assign valid source and detector pairs

Generate
Mesh

Define anomaly region

Assign BFI 𝒓 for background and anomaly by
updating 𝜇𝑎 𝒓 t 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 𝒓, 𝜏
Calculate for
Multiple
m

e to calculate boundary 𝐺1 𝒓, 𝜏

Save boundary data of 𝐺1 𝒓, 0 and BFI 𝒓

Save Data

Chart 1: Flowchart outlining the sequence and commands used in the modified
NIRFAST to generate a forward model for ncDCT.

Solving the inverse problem for image reconstruction is conducted on a second mesh
with a coarse finite element division (pixel basis) (87, 88) (see Chart 2). Initial values of
background BFI and optical properties (𝜇𝑎 (𝒓) and 𝜇𝑠′ (𝒓)), along with the selected 𝜏 are
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assigned to generate a homogeneous inverse mesh. The simulated or measured boundary
BFI data are converted to 𝑔1 (𝒓, 𝜏) at the selected τ using the semi-infinite analytical
expression of Equation 2.8 (67, 83, 89, 90), and further converted to 𝐺1 (𝒓, 𝜏) by
multiplying with 𝐺1 (𝒓, 0). The boundary 𝐺1 (𝒓, 𝜏) functions are then input into the inverse
model to reconstruct the 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) distribution inside the entire tissue volume. The BFI
distributions are finally extracted through the definition of 𝜇𝑎𝑑 (𝒓, 𝜏) . Note that even
though we can reconstruct 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) distribution directly from the simulated or
measured boundary 𝐺1 (𝒓, 𝜏) data, we chose to extract boundary BFI values first and then
convert them back to 𝐺1 (𝒓, 𝜏) for image reconstruction. This seemingly redundant
procedure is yet essential for the normalization of BFIs in real measurements (see
Chapter 5.2.3) as well as reducing the noise influence on the measured 𝐺1 (𝒓, 𝜏).

2.4.2 Noise Model for DCT
To evaluate noise influence on image reconstruction through simulations, randomized
noise varying at different τ are generated based on a noise model originally derived for
DCS (83, 91). The noise level depends on the detected photon count rate (i.e., light
intensity) at each S-D pair, which is estimated using the light intensity detected from in
vivo tissues (e.g., breast tissue). This noise is applied to the simulated 𝑔2 (𝒓, 𝜏) curves.
Multiple 𝑔2 (𝒓, 𝜏) curves with noise are generated for each S-D pair and then averaged to
improve the signal-to-noise ratio. This simulation mimics our in vivo measurements and
data averaging process. Finally, 𝑔2 (𝒓, 𝜏) curves are converted to 𝐺1 (𝒓, 𝜏) to generate
boundary BFI data.
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Load the same homogeneous mesh established in
the forward problem
Assign initial guess of 𝜇𝑎 𝒓 , 𝜇𝑠 ′ 𝒓 and
𝒓
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Chart 2: Flowchart outlining the sequence and commands used in the modified
NIRFAST to solve DCT inverse problem.
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CHAPTER 3 NONCONTACT DIFFUSE CORRELATION TOMOGRAPHY
(NCDCT) SYSTEM

3.1 Introduction
Most DCS systems employ contact-based interaction with the sample. However, in
tissues, contact measurements can promote hemodynamic variations induced by probe
compression or disturbing sensitive areas. Our lab has recently developed a noncontact
DCS system that uses a lens-focusing technique to avoid the contact influence (89, 92).
The probing depth of the noncontact DCS measurement was fixed due to the single
source-detector (S-D) separation design. To further extend the DCS technique to
tomographic imaging, an ncDCT system has recently been developed. The ncDCT probe
has multiple S-D measurement pairs (10-30 mm S-D separations) and the system
employs a motorized stage for automatic and precise scanning over the region of interest
(ROI) (37). In addition, the finite-element-method based facilitation of DCT image
reconstruction as mentioned above enables blood flow imaging on arbitrary boundary
geometries. Finally, validation efforts have been made including computer simulations
and phantom tests. The unique noncontact imaging system remedies many of the
concerns mentioned at beginning of the thesis (Chapter 1.3).
In this chapter, the ncDCT system instrumentation is first presented in Chapter 3.2.
Chapter 3.3 describes the procedures to perform blood flow imaging, which includes
ncDCT scanning (Chapter 3.3.1) and FD NIRS measurements (Chapter 3.3.2). To
validate the imaging capability of the ncDCT system, computer simulations and tumorlike phantom experiments with varied flow contrasts are provided based on a simple slabshaped tissue boundary (i.e., semi-infinite geometry) (Chapter 3.4) (37). Since liquid
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(Intralipid solution) and solid phantoms (silicone) are commonly used in instrument
calibration/characterization and algorithm validation, the fabrication procedures for
phantoms are provided at the end of this section (Chapter 3.5).

3.2 ncDCT Instrumentation
Extending DCS to DCT attaches the burden of collecting many boundary
measurements. As such, our noncontact probe was upgraded to have two identical laser
source paths and one detector path configured in a linear array (Figure 3.1c). In each
source path, output from a multimode source fiber (WF200/220/245, CeramOptec, MA,
USA) connected to a laser (825 nm) on the DCS instrument is projected onto the tissue
through lenses (Figure 3.1a). Fifteen single-mode detector fibers (SM800-5.6-125,
Fibercore, CA, USA) are equally arranged in a 7 mm line to cover a 20 mm range
through the magnification of lenses (Figure 3.1c). The S-D separations vary from 10 to
30 mm, thus enabling up to ~15 mm penetration depth (37). Two long coherence lasers at
825 nm (coherence length >5 m, CrystaLaser, NV, USA) emit light to tissue through
individual source paths, alternatively. The photons traveling through the tissue sample are
collected by the detector array of 15 avalanche photodiodes (APD, Perkin Elmer, Canada)
through the detector path. A multi-channel autocorrelator (Correlator.com, NJ, USA)
takes the APD outputs and calculates 15 intensity correlation functions simultaneously
(Figure 3.2a). A motorized stage (CR1-Z7, Thorlabs, NJ, USA) is integrated into the
optical system which rotates the ncDCT probe around the nipple for scanning a ROI on
the breast surface (Figure 3.1a). A linear stage (5236A16, McMASTER-CARR, IL, USA)
and a custom-made rotational platform were used to manually align the axis of probe
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head at the center of ROI and perpendicular approximately to the breast tissue surface
(Figure 3.1a). The outcomes from this scanning are the boundary data of intensity
autocorrelation functions collected at hundreds of S-D pairs on the ROI.
Y
Rotational stage

(a)

(c)
X
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Manual stage

Unit: cm
1

Fibers
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Scanning
Breast tumor track

ROI

Figure 5
Figure 3.1: The schematic diagram of ncDCT scanning system. (a) A motorized
rotational stage was used to scan over a representative ROI on the breast and the rotation
axis was aligned through the nipple; (b) During scanning procedure, the source and
detector rays were perpendicular to the breast surface and rotationally scanned around the
nipple to cover the tumor bearing ROI; (c) Fifteen single-mode detector fibers were
equally projected onto breast surface to cover a 2 cm range while two multimode fibers
were projected onto two sides of the linear arrays, enabling S-D separations to span from
1cm to 3 cm.

3.3 Blood Flow Imaging Protocols
3.3.1 ncDCT Scanning
To demonstrate the scanning protocol for 3-D blood flow imaging in breast tissue, a
plastic mannequin is placed on the bed to mimic patients lying in a supine position

25

(Figure 3.2b). A red mark made on the mannequin breast surface indicates a tumor
beneath the skin surface. The rotation axis in the ncDCT probe (Figure 3.1a) is first
aligned with breast nipple. The probe is then rotated to the top of the red mark and
adjusted the working distance and projection angle to make the two source rays
approximately perpendicular to the mannequin breast surface. In order to scan over the
ROI, the probe is rotated back to the first scanning position and then scans certain
degrees over a ROI through multiple steps with a 3-degree increment per step. The first
and last scanning steps cover healthy breast tissue and the middle step is usually on top of
the lesion mark. Total scanning time was ~25 minutes with 60 s sampling time per step at
1 Hz DCS sampling rate for each laser source. During the scanning process, two
projected source pairs at the first and last steps are marked on the breast surface using a
marker pen.

3.3.2 Commercial 3-D Camera Scanning
After ncDCT probe scanning, a commercial 3-D camera (NextEngine, CA, USA) is
used to take the surface geometry of the mannequin breast with source and rotation center
marks. The working distance is ~17 inch from breast surface, the field of view (FOV) is
10  13 (Figure 3.2b), and the total acquisition time is ~5 minutes. After that, the
mannequin is removed and a small foam pad perpendicular to the rotation axis is attached
to ncDCT probe as a reference plane (RP) (Figure 3.2c). The 3-D camera is used to take
an image of the RP to co-register the two coordinate systems: ncDCT system and 3-D
camera, which enables the alignment of the scanned source and detector locations onto
the breast-shaped mesh. The sequence of taking RP image by 3-D camera is after all
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measurements in in vivo measurement due to busy clinical workflow and it is described in
later chapter (Chapter 5.2.2).

16 Channel
DCS Detectors

(b)

Imagent Detectors

(c)

(a)

Figure 6
Figure 3.2: (a) Photo of the combined ncDCT imaging system and a commercial
frequency-domain tissue oximeter for tissue optical properties measurement. (b) The
breast surface with source marks was imaged by the 3-D camera. (c) After the mannequin
was removed, a small foam pad was attached to the DCS scanner. The 3-D camera took
another image to include the small foam pad whose surface (RP) was adjusted
perpendicularly to the rotation axis. The RP was used for the co-registration of two
coordinates: 3-D camera and ncDCT system.
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3.3.3 Frequency-domain NIRS Measurements
Following the ncDCT measurement, a commercial FD tissue oximeter (Imagent, ISS,
IL, USA) (71) was used to measure 𝜇𝑠′ and 𝜇𝑎 of the breast tissue. The Imagent
instrument includes 110 MHz modulated sources at 4-wavelength (690, 750, 780, and
830 nm), photomultiplier tubes, and desktop computer control, which ultimately
calculates tissue optical properties (µa and µs’) (Figure 3.2a). Source and detector fibers
are embedded in a black flexible probe and the probe is gently placed on the skin surface
to measurement breast tissue optical properties at certain positions. The measurement
usually takes ~ 5 minutes.

3.4 ncDCT Validation Results
In this subsection, initial validation work including computer simulations and
phantom experiments on slab-shaped geometry with linear probe scanning were
performed to evaluate the accuracy of our ncDCT system. To test our theoretical DCT
technique, computer simulation was first conducted in homogeneous situation (i.e., no
anomaly) to evaluate the forward solution (Chapter 3.4.1). Computer simulations and
phantom experiments embodied recovery of anomaly flow contrasts were performed to
further evaluate the inverse solution (Chapter 3.4.2). Background optical properties
mismatch was also induced in computer simulations and phantom experiments to
evaluate their crosstalk on reconstructed flow contrasts (Chapter 3.4.3).
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3.4.1 Forward Solution Validation
A slab mesh simulating liquid phantom solution [dimension (mm): 90 (H)

90 (W)

35 (D)] was first generated in SolidWorks® (Dassault Systemes, MA, USA) and then
segmented into finite elements using ANSYS® (ANSYS, PA, USA). A total of 73949
nodes were created with node distances of 2 mm. The segmented mesh nodes and
elements information were then input into MATLAB® (MathWorks, MA, USA) to
generate all mesh files needed for the simulations with NIRFAST. Optical properties
were set throughout at 𝜇𝑠′ = 8.00 cm-1 and 𝜇𝑎 = 0.045 cm-1 close to breast tissue values
(93). The blood flow index (BFI) for the background was set as 1

10-8 cm2/s close to

Intralipid phantom values (58, 67). The noncontact probe scanned linearly (mimicked in
simulation) across the ROI in 15 steps with an increment of 4 mm/step generating a
scanning area of 40 mm

56 mm and 450 (15 steps

15 APDs

2 sources) effective S-

D pairs (Figure 3.3). The forward solution (i.e., 𝐺1 (𝒓, 𝜏)) was calculated by the modified
NIRFAST with 𝜏 from 0 to 8

10-6 s. Minimal simulation aberrations over the measured

ROI (1% mean discrepancy and 1.45% standard deviation) were observed between BFI
extracted using the established semi-infinite analytical solution (37) in Equation 2.6
(Chapter 2) and the assigned BFI. The computer simulation validated the algorithm for
calculating forward solution using Equation 2.6 based on NIRFAST.
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Figure 3.3: Illustration of the ncDCT system linearly scanning across the ROI of liquid
phantom surface with a pump-connected cylindrical tube placed inside the tank.

3.4.2 Inverse Solution Validation
Computer Simulations. A cylindrical tube-shaped anomaly [dimension (mm): 13
(Dia.)

80 (L)] was inserted beneath the middle of the ROI with a depth of 12.5 mm

from the tube center to the ROI surface (Figure 3.3). The 𝜇𝑎

𝜇𝑠′ inside the anomaly

were matched to the background tissue. The attributed anomaly BFI was increased from
0-fold to 20-fold at 4-fold increment per step. Reconstruction was conducted on the same
mesh with a pixel basis of 20
time 𝜏1 = 3.2

20

25 (node number: 11,025) and at selected delay

10-6 s. Due to limited ROI dimensions along the tube, only partial

anomaly reconstruction was possible (Figure 3.4a). For percentage flow change
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comparison, the reconstructed anomaly peak flow value was normalized to the averaged
step differences of BFI. Both the shape (Figure 3.4a) and relative anomaly peak flow
contrast changes (Figure 3.4b) were well reconstructed (regression slope = 1.00, R2 =
1.00 and p < 10-5). The anomaly was extracted with the full width half-maximum
(FWHM) criterion (94) on the reconstructed DCT image. The averaged BFI of the
reconstructed anomaly was computed by averaging the BFIs within the anomaly. An
excellent linear relationship was also observed between the reconstructed and assigned
percentage flow changes (data are not shown; regression slope = 1.00, R2 = 1.00 and p <
10-5).
Phantom Experiments. A background of tissue-like liquid phantom was placed in an
aquarium and a pump-connected cylindrical tube anomaly was filled with liquid and
small pieces of solid phantom (Figure 3.3). The tissue-like liquid phantom (Chapter
3.5.1) was comprised of Intralipid, distilled water and India ink, and has been used
extensively for DCS calibrations (92). Intralipid particles (Fresenius Kabi, Sweden)
provide control of scattering (𝜇𝑠′ ) and Brownian motion (𝐷𝐵 ; 𝛼 ≈ 1) while India ink
controls absorption ( 𝜇𝑎 ). We set 𝜇𝑠′ = 8.10 𝑐𝑚−1 and 𝜇𝑎 = 0.044𝑐𝑚−1 while
quantifying them with Imagent (Figure 3.2a). To create flow index contrasts against the
background, a clear plastic tube [dimension (mm): 13.5 (Dia.)

80 (L)] with a very thin

wall (0.35 mm) was placed at ~12.5 mm (tube center to ROI surface) into the background
liquid phantom (Figure 3.3). The tube was mostly filled with small pieces of solid
phantom (𝜇𝑠′ = 10.00 cm-1 and 𝜇𝑎 = 0.10 cm-1) to randomize pumped particle motions as
Brownian motion and generate a diffusive circumstance for photons. Solid phantoms
were comprised of titanium dioxide, silicon and carbon black (Chapter 3.5.2). A
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peristaltic pump (HV-77201-60, Cole Parmer, IL, USA) connected in series with a
hydraulic capacitor that damped fluid pulsations was employed to create step increases in
steady flow from 0 to 20 ml/min at 4 ml/min increments within the tube. The noncontact
probe was first calibrated to the homogeneous liquid phantom region. The scanning
procedure was linear as assumed in simulations. Total scanning time was ~20 minutes
with 60 s sampling time per step at 0.5 Hz DCS sampling rate for each laser. We used
identical reconstruction parameters as the simulation including slab mesh and delay time
𝜏1 with the exception of a median filter application. This latter addition assisted in
stabilizing inherent experimental noise not encountered in the ideal simulation (87). The
relationship between macro pumped flow (unit: ml/min) and micro particle motion (𝛼𝐷𝐵
unit: cm2/s) is complicated, but was confirmed linear (95). For this case the assigned flow
represents the macro flow (pump speed) rather than DCS indices. Figure 3.4d presented
relative macro and micro flow changes using the same way as in simulations. A tubeshaped anomaly was clearly observed after image reconstruction (Figure 3.4c). The
reconstructed flow indices accurately captured the flow changes in the tube when
quantified with the peak value (Figure 3.4d; linear regression slope = 0.97, R2 = 1.00 and
p < 10-5) and with the mean of extracted anomaly (data are not shown; linear regression
slope = 0.99, R2 = 0.96 and p < 10-3).
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Figure 3.4: Results of computer simulation and phantom experiment utilizing a
homogeneous slab background and internally placed tube-shaped anomaly of varied flow
contrast. The reconstructed anomaly from the last step with highest flow contrast is
shown (a) 3-D overlaid on the assigned anomaly and (c) in the phantom experiment. Both
(b) and (d) show a linear relationship between the assigned anomaly and reconstructed
flow indices expressed as ratios of relative changes respectively in the simulation and
phantom experiment. 3-D data are displayed with open source visualization software
PareView (Kitware, NY, USA).

3.4.3 Influence of Optical Property Mismatch on ncDCT Accuracy
We note that no optical property mismatch between anomaly and background was
induced, i.e., ∆𝜇𝑠′ = 0 and ∆𝜇𝑎 = 0, in the computer simulations and phantom tests
performed earlier. However, our previous published studies have showed that the
mismatch of 𝜇𝑎 and 𝜇𝑠′ can result errors in estimating DCS flow index (67). In the
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following computer simulation and phantom experiments, the influence of 𝜇𝑎 and
𝜇𝑠′ mismatch on ncDCT flow contrast reconstruction is presented below.
The Influence of 𝝁′𝒔 on DCT. Recall that 𝜇𝑠′ = 8.00 cm-1 and 𝜇𝑎 = 0.045 cm-1 in the
previous experiments. In this computer simulation, the 𝜇𝑠′ of background was changed to
3.2 cm-1 to generate a 250% 𝜇𝑠′ contrast (8.0/3.2) in the anomaly. For the phantom
experiment, the new background 𝜇𝑠′ was accomplished by adjusting the concentration of
Intralipid and was measured/verified by Imagent. Flow indices were reconstructed under
two experimental conditions: (1) assign homogenous optical properties in the forward
and inverse solutions ( 𝜇𝑎 = 0.045 𝑐𝑚−1 , 𝜇𝑠′ = 8.0 𝑐𝑚−1 ) for both the anomaly and
background; (2) assign separate property values for the anomaly (𝜇𝑎 = 0.045 𝑐𝑚−1 , 𝜇𝑠′ =
8.0 𝑐𝑚−1 ) and background (𝜇𝑎 = 0.045 𝑐𝑚−1 , 𝜇𝑠′ = 3.2 𝑐𝑚−1) in the forward solution
and use a homogenous mesh ( 𝜇𝑎 = 0.045 𝑐𝑚−1 , 𝜇𝑠′ = 3.2 𝑐𝑚−1 ) for image
reconstruction. The differences in the reconstructed flow index contrasts between the two
conditions were compared.
Figure 3.5 shows the computer simulation results. In Figure 3.5a, the reconstructed
flow index contrasts under Condition #2 were normalized to those under Condition #1 for
comparisons. The underestimations of µ′s contrasts under Condition #2 (i.e., assuming
𝜇𝑠′ = 3.2 𝑐𝑚−1 in the anomaly) resulted in similar overestimations (ratios) of flow
contrasts at different flow levels. However, the relative changes of flow contrasts over the
large range of flow variations were not influenced by the incorrect assumptions of 𝜇𝑠′
(Figure 3.5b). Figure 3.6 shows the phantom experimental results, which are very
similar to those in computer simulations (Figure 3.5).
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Figure 9
Figure 3.5: Computer simulation results. (a) The underestimations of 𝜇𝑠′ in the anomaly
generated the overestimations of flow contrasts (red bars). (b) Linear relationships
between the assigned and reconstructed flow index contrasts expressed as ratios of
relative changes reconstructed under Condition #1 (blue dots) and Condition #2 (red dots).
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(a)

(b)

Figure 10
Figure 3.6: Phantom experimental results. (a) The underestimations of 𝜇𝑠′ in the anomaly
generated the overestimations of flow contrasts (red bars). (b) Linear relationships
between the assigned and reconstructed flow index contrasts expressed as ratios of
relative changes reconstructed under Condition #1 (blue dots) and Condition #2 (red dots).
The Influence of 𝛍𝐚 on DCT. Similar to the evaluation of 𝜇𝑠′ influence, we use
computer simulations to set up 2- and 3-fold contrasts of anomaly 𝜇𝑎 with the
background. In the reconstruction, we ignored the variations of 𝜇𝑎 in the anomaly
(0.09 cm−1 and 0.135 cm−1 ) and reconstructed flow contrasts using the background
optical properties (𝜇𝑎 = 0.045 𝑐𝑚−1 and 𝜇𝑠′ = 8.0 𝑐𝑚−1). Reconstructed flow contrasts
were normalized to the homogeneous case (i.e., no 𝜇𝑎 anomaly/background contrast).
Figure 3.7 shows that the underestimations of 𝜇𝑎 contrasts resulted in the
36

underestimations in flow contrasts (Figure 3.7a). However, the relative changes of flow
index contrasts over the large range of flow variations were not influenced by the
incorrect assumptions of 𝜇𝑎 (Figure 3.7b).

(a)

(b)

Figure 11
Figure 3.7: Computer simulation results. (a) The underestimations of 𝜇𝑎 generated the
underestimations of flow contrasts (green and red bars). (b) Linear relationships between
the assigned and reconstructed flow indices expressed as ratios of relative changes
reconstructed using different 𝜇𝑎 values.
In summary, inaccurate µs’ assumptions resulted in much greater flow index errors
than inaccurate µa assumptions. Specifically, ~250% underestimation of µs’ led to
245 ± 2% overestimation of flow indices in simulations and 297 ± 40% overestimations
in phantom experiments, whereas 200% to 300% underestimation of µa led to 11.5 ± 2%
to 26 ± 3% underestimations of flow indices, respectively. All these results are
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consistent with our previous studies using DCS (67, 83). Nevertheless, the relative
changes of flow index contrasts over the large range of flow variations can be accurately
reconstructed even with the incorrect assumptions of optical properties.

3.5 Discussion and Conclusions
In this chapter, the instrumentation of our newly developed ncDCT system for 3-D
blood flow contrast imaging was reported. A plastic mannequin was used to demonstrate
the blood flow imaging protocol for breast tumor detection. The procedures to collect
breast boundary blood flow index and surface geometry were described in detail.
We further validated the ncDCT system for the flow contrast imaging using computer
simulations and tissue phantom tests. The results indicated that the cylindrical tubeshaped anomaly inside homogenous background tissue can be clearly reconstructed and
high correlation was observed between the reconstructed and assigned anomaly flow
contrast. We also found inaccurate µs’ assumptions resulted in much greater flow index
contrast errors than inaccurate µa. These findings suggest that investigations involving
significant µa and µs’ changes should concurrently measure flow indices and optical
properties for avoiding over/underestimation of flow indices.

However, the relative

changes of reconstructed flow index contrasts can be accurately reconstructed even with
the incorrect assumptions of optical properties.
In conclusion, a novel ncDCT system was built for blood flow contrast imaging in
deep biological tissue. The imaging capability was validated through both computer
simulations and phantom experiments based on slab-shaped geometry with linear
scanning protocol.
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3.6 APPENDIX: Recipes for Making Tissue-like Phantoms
Optical phantoms are constructed to mimic the optical absorption and scattering, and
particle Brownian motion (only liquid phantom) of tissue. In our lab, liquid and solid
phantoms are made to provide a tissue model for probe calibrations, titration experiments
and testing image reconstruction algorithms.

3.6.1 Liquid Phantom Creation: Intralipid
In our lab, distilled water, India ink (Black India 44201, Higgins, MA) and Intralipid
(30%, Fresenius Kabi, Uppsala, Sweden) are utilized in constructing liquid phantoms
which provide a homogeneous tissue model (41, 67, 92). India ink is used to manipulate
µa (λ) and has minimal influence on phantom scattering. The µa (λ) values at certain
wavelengths are calculated based on the concentration of India ink. Intralipid is used to
control µs’ (λ) via changing its concentration and provides particle Brownian motion (DB;
α ≈ 1). The absorption of the lipid particles is negligible. Distilled water contributes little
to both absorption and scattering, allowing for larger phantom volumes to facilitate
satisfying the semi-infinite geometry model. Based on the desired values of µa (λ) and µs’
(λ) for the phantom, the liquid phantom creation procedure is given bellow.
Calculation of Ink Volumes for Desired Absorptions. The India ink needs to be
diluted to 10% concentration (or lower concentration, which depends on the volume of
the aquarium holding liquid phantom), due to the very high absorption of pure India ink.
The absorbance of the 10% ink solution should be measured with the spectrometer
(Beckman Coulter, CA, USA). Since the 10% ink solution is not within the measurable
range of our spectrometer, it is further diluted to 0.025% concentration. Multiple samples
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of 0.025% ink solution are measured by spectrometer at 690, 750, 780 and 830 nm
(matching the Imagent source wavelengths) and the measured absorbance is further
converted to absorption coefficient by the equation: 𝜇𝑎 (𝜆) =

(10)

𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝜆)

(9). This 𝜇𝑎 (𝜆) is for 0.025% concentration ink solution. Therefore, one needs to
multiply 𝜇𝑎 (𝜆) by a factor of 400 for the absorption coefficient of 10% ink solution
(𝜇𝑎 𝑖𝑛𝑘 (𝜆) ). As Intralipid is primarily comprised of water, it is assumed to have an
absorption coefficient equivalent to water (𝜇𝑎 𝑤𝑎𝑡𝑒𝑟 = 𝜇𝑎 𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 ). The 𝜇𝑎 𝑤𝑎𝑡𝑒𝑟 (𝜆) values
at those wavelengths can be obtained from the literature (96). Knowing the desired value
of absorption coefficient for the phantom ( 𝜇𝑎

𝑝ℎ𝑎𝑛𝑡𝑜𝑚

(𝜆) ) and the volume of total

phantom solution (𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 ), the volume of 10% ink solution (Vink) can be determined
as:
𝜇𝑎 𝑤𝑎𝑡𝑒𝑟 (𝜆)

(𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 − 𝑉𝑖𝑛𝑘 ) + 𝜇𝑎

𝑖𝑛𝑘

(𝜆)

𝑉𝑖𝑛𝑘 = 𝜇𝑎

𝑝ℎ𝑎𝑛𝑡𝑜𝑚

(𝜆)

𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚

(3.1)

The volume of distilled water is simply the remaining volume to be filled (i.e., 𝑉𝑤𝑎𝑡𝑒𝑟 =
𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 −𝑉𝑖𝑛𝑘 − 𝑉𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 ).
For the titration experiment, 10% ink solution is added to the phantom at each step to
increase 𝜇𝑎

𝑝ℎ𝑎𝑛𝑡𝑜𝑚

(𝜆). The volume of 10% ink solution to be added is described by the

following equation:
𝑏𝑒𝑓𝑜𝑟𝑒

𝜇𝑎

𝑏𝑒𝑓𝑜𝑟𝑒

phantom

(λ) × 𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 + 𝜇𝑎

𝑎𝑓𝑡𝑒𝑟

ink

𝑎𝑑𝑑
(λ) × 𝑉𝑖𝑛𝑘
= 𝜇𝑎

𝑎𝑓𝑡𝑒𝑟

𝑎𝑑𝑑
(λ) × (𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 + 𝑉𝑖𝑛𝑘
)

phantom

(3.2)
where the “before” and “after” indicate the procedure of adding ink solution.
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Calculation of Intralipid Volume for Desired Scattering. According to van
Staveren’s Mie theory approximation (97), 𝜇𝑠′ (𝜆) of 10% Intralipid is given by the
equations:
𝜇𝑠 = 2.54

109

𝑔 = 1.1 − 0.58

𝜆−2.4

(3.3)

10−3 𝜆

(3.4)

𝜇𝑠′ = 𝜇𝑠 (1 − 𝑔)

(3.5)

where λ is in [nm] and 𝜇𝑠 and 𝜇𝑠′ are in [cm-1]. The 𝜇𝑠′ (𝜆) of 10% Intralipid multiplies a
factor of three can generate 𝜇𝑠′ (𝜆) of 30% Intralipid (denoted as 𝜇𝑠′ 𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 (𝜆)). As
there are expected to be no contributions to the phantom scattering by the 10% ink
solution or distilled water, both are ignored in calculation. Knowing the desired value of
reduced scattering coefficient (𝜇𝑠′ 𝑝ℎ𝑎𝑛𝑡𝑜𝑚 (𝜆)), the volume of 30% Intralipid to be used
can be calculated by equation:
𝜇𝑠′ 𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 (𝜆)

𝑉𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 = 𝜇𝑠′ 𝑝ℎ𝑎𝑛𝑡𝑜𝑚 (𝜆)

𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚

(3.6)

3.6.2 Solid Phantom Creation: Silicone
Solid phantoms are useful for simulating tissue-like geometry and do not deteriorate
as the liquid phantom. Among the choices of solid phantoms, there are mainly three kinds
of phantom matrix, including gelatin, resin and room temperature vulcanization (RTV)
silicone (98, 99). The gelatin (also called agar) phantom is the cheapest, however, it is the
least usable and can become fragile and crumble under applied stress. Both of the other
two phantoms are stiff and stable. Their fabrication procedures and functions are very
similar. Previous study showed by reducing the hardener in RTV silicone phantom,
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stiffness of the phantom can be reduced, shaping this material into more biologically
relevant configuration (100). In our lab, the RTV silicone phantom is used.
Soft rubber texture similar to stiff tissue phantom can be made out of silicone and
used for years. Titanium dioxide (TiO2) and carbon black are added to provide scattering
and absorption contrast. Careful preparation is required for prevention of bubbles and
proper curing. A recipe and fabrication procedure is listed below.

(a)

(b)

Figure 12
Figure 3.8: Photographs of (a) an empty mold that four facets can be disassembled and
(b) a cured silicone phantom

RTV Silicone Phantom Recipe
Ingredients: 1. Silicone and hardener (RTV-615 silicone optical 2-part flow clear RTV
SS4120-1P primer required, Circuit Specialists Inc, Mesa, AZ)
2. Scatterer (Titanium (IV) Oxide, Alfa Aesar, Chicago, IL)
3. Absorber (Carbon Black (99.9+% pure), Alfa Aesar, Chicago, IL)
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Tools: 1. Mold (Figure 3.8a, do not use silicone or rubber molds)
2. Mixing bowl
3. Mortar and pestle for mixing TiO2 and carbon black
4. Spatula for mixing silicone and hardener
5. Blender with at least a 0.25 HP motor and a 1 liter container
6. Balance (scales) with at least 0.01g mass resolution and weighing paper
7. Rubber gloves
8. Dust mask
9. Tight-lidded containers, suitable for long-term storage
10. Hair dryer

Assembly Sequence:
Since the amount of carbon black (CB) needed is tiny compared with TiO2, we
usually first make sufficient amount of 1:100 CB/TiO2 mixture and then mix the CB/TiO2
mixture with pure TiO2 to achieve the expected optical properties.
1. Make the 1:100 carbon black (CB) / TiO2 mixture.
1) Weigh out 1.8 g TiO2 and 0.2 g CB to make 1: 9 CB / TiO2 mixture and mix them
completely with mortar and pestle. Then transfer the mixture to a container.
2) Weigh 0.1∗N g mixture made in 1) and 0.91∗N g pure TiO2 to make 1:100 CB / TiO2
mixture. The mixture should be completely mixed with clean mortar and pestle. Then
transfer the final mixture to a container and label it.
Because the exact ratio of CB to TiO2 in a mixture is hard to control or determine,
the absorptivity of each mixture must be found. (Since carbon black is very “sticky”
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and very little is used, it is difficult to account for all the carbon black lost to the
insides of the mortar/pestle, etc.)
2. Determine the absorptivity of the mixture in units of cm-1∙g-1∙306 g silicone kit.
1) Make a test silicone phantom with certain amounts of 1:100 CB/TiO2 mixture and
pure TiO2. According to the experience, ~ 0.0446 g 1:100 CB/TiO2 mixture and
~0.4177 g pure TiO2 make 𝜇𝑎 ≈ 0.061 𝑐𝑚−1 and 𝜇𝑠′ ≈ 10.3 𝑐𝑚−1.
2) Measure the optical properties 𝜇𝑎 and 𝜇𝑠′ with the commercial frequency-domain
tissue oximeter. Measured 𝜇𝑎 subtract 0.01 cm-1 is the 𝜇𝑎 contributed by CB at 750
nm wavelength (the 𝜇𝑎 of silicone is constant at ~0.01 cm-1).
3) Divide the mass of the mixture used by the corrected absorption coefficient. This is
the absorptivity of the CB/TiO2 mixture in units of cm-1∙g-1∙306 g silicone kit.
𝑎𝐶𝐵/𝑇𝑖𝑂2 =

(𝜇𝑎 −0.01)
𝑀𝐶𝐵/𝑇𝑖𝑂2

(3.7)

where 𝑎𝐶𝐵/𝑇𝑖𝑂2 is the absorptivity, 𝜇𝑎 is the measured absorption coefficient, and
𝑀𝐶𝐵/𝑇𝑖𝑂2 is the mass of 1:100 CB/TiO2 mixture used to make the test phantom. Here
it is assumed that one 306 g silicone kit was used to make the phantom.
3. Make the solid phantom with target optical property
1) Calculate the mass of CB/TiO2 mixture needed according to the targeted 𝜇𝑎 of the
phantom:
𝑀𝐶𝐵⁄𝑇𝑖𝑂2 = 𝑎(𝜇𝑎 −0.01) ∙ 𝑁𝐾
𝐶𝐵⁄𝑇𝑖𝑂2

(3.8)

where 𝜇𝑎 is the expected absorption coefficient, 𝑎𝐶𝐵⁄𝑇𝑖𝑂2 is the absorptivity of the
CB/TiO2 mixture measured from the test phantom, and NK is the number of 306 g
silicone kit used (can be fraction). Previous study using similar CB as absorbing agent
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has reported the linear relationship between the mass of CB and phantom 𝜇𝑎 under
𝜇𝑎 = 0.1 cm-1(9).
2) Calculate the mass of TiO2 needed according to the targeted 𝜇𝑠′ of the phantom. The
relationship between the mass of TiO2 used and the 𝜇𝑠′ is roughly 0.024 cm-1g-1306 g
silicone kit, at 750 nm wavelength.
𝜇′

𝑠
𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2 = 0.024
∙ 𝑁𝐾

(3.9)

where 𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2 is the mass of TiO2, 𝜇𝑠′ is the targeted 𝜇𝑠′ and NK is the number of
306 g silicone kit used. The value, 0.024 is only a rough estimate based on previous
phantom made with the same TiO2 powder. Then the mass of pure TiO2 added
besides the CB/TiO2 mixture is:
𝑀𝑎𝑑𝑑𝑒𝑑−𝑇𝑖𝑂2 = 𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2 − 𝑀𝐶𝐵⁄𝑇𝑖𝑂2

(3.10)

3) Mix the CB/TiO2 mixture and pure TiO2 powder.
Mix the new mixture completed in the mixing bowl. Then transfer it to the NK ∙
306 g silicone in the blender. Mix them for totally 10 min with 10 sec at each time.
4) Mix the silicone with hardener.
First, weigh

1
10

∙ 𝑁𝐾 ∙ 306 g silicone hardener. It should be noted that reduce the

amount of hardener may decrease the stiffness of the cured phantom. Then, transfer
the mixture to a clean mixing bowl after the power and silicone mixture is completely
cooled off and no bubbles left. The hair dryer on “cool” can be used to blow air on
the surface of the phantom to break up any bubbles or foam. Slowly add the hardener
to the silicone. Gently and thoroughly mix them with the spatula. Make sure no air
bubble is induced.
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5) Transfer the mixture equally into the phantom mold. Cover the mold with clean sheet
and let it sit in the room temperature for ~1 day.
6) After the phantom is cured, disassemble the mold and remove the phantom. Since the
cured phantom attaches the mold very tightly, it is not easy to remove the phantom
from the mold. The mold we used is customized that the four facets can be
disassembled.
7) Clean the tools.
Since the silicone is very viscous, it may flow very slowly. It cannot dissolve in
the water. So to clean the blender, just place the blender bottle upside down in a place
lined with a plastic bag overnight and most of the silicone may flow away.
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CHAPTER 4 COMPUTER SIMULATIONS FOR NCDCT OF BREAST TUMORS

4.1 Introduction
The recently developed ncDCT in our laboratory provides a unique tool for threedimensional (3-D) flow imaging of deep tissue (37). Initial validation efforts for the
innovative ncDCT system have been made using computer simulations and tumor-like
phantoms on a simple semi-infinite geometry (see Chapter 3). To translate this novel
technique to clinical use for breast tumor imaging, the imaging ability of arbitrary
boundaries (e.g., breast shape) is necessary. In this chapter, computer simulations are
carried out to characterize the performance of ncDCT system for imaging an anomaly
(tumor) with varied flow contrasts and depths inside the tissue volumes under breastshape tissue boundary.

4.2 Computer Simulation Protocols
We conducted several computer simulations to characterize the performance of
ncDCT system. The first simulation tested the abilities of ncDCT in recovery of an
anomaly (tumor) beneath the surfaces of a slab and a female plastic mannequin breast
(Chapter 4.2.1). The second simulation evaluated the reconstruction accuracies of the
anomaly with varied depths and flow contrasts in the same plastic mannequin breast. The
influence of noise on ncDCT image reconstruction was also assessed and compared with
the results without noise (Chapter 4.2.2). The next simulation applied a priori structural
knowledge of the anomaly in the inverse mesh to improve the accuracy of flow image
reconstruction (Chapter 4.2.3). The last simulation evaluated the influence of different
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delay time τ selection on ncDCT image reconstruction and the optimized τ selection was
provided (Chapter 4.2.4).

4.2.1

Reconstruction of a Tumor in Slab-shaped and Breast-shaped Tissue Volumes

To evaluate the reconstruction of an anomaly inside a background tissue volume with
a simple semi-infinite geometry, a slab volume [dimension (mm): 100 (H)

100 (W)

40 (D)] was first generated in SolidWorks and then segmented into finite elements using
ANSYS. A total of 15996 nodes were created with node distances of 3 mm and 6 mm in
the region of interest (ROI) and the surrounding region, respectively (Figure 4.3a).
Different mesh resolutions were employed to reduce the total node number while
maintaining appropriate spatial resolution in the ROI. The segmented mesh nodes and
elements information were then input into MATLAB to generate all mesh files needed
for the simulations with NIRFAST. The slab volume mesh represented a healthy
background tissue volume. A spherical anomaly with a diameter of 10 mm mimicking a
tumor was then placed at the ROI center and the anomaly centroid location was 7 mm
beneath the surface of background tissue volume (Figure 4.3a). Optical properties for
both tumor and background tissues were set homogeneous throughout the entire slab as
μs’ = 6.00 cm-1 and μa = 0.06 cm-1. The blood flow indices for the background and
anomaly were set as 1

10-8 cm2/s and 10

10-8 cm2/s, respectively, resulting in a 10-

fold flow contrast between the tumor and surrounding normal tissues (Figure 4.3c). The
ncDCT probe with a linear S-D array scanning rotationally over the ROI was simulated
for 21 steps with 3 degrees per step to collect the boundary data (Figure 4.3a). There
were totally 42 sources and 315 detectors distributed on the ROI according to the
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scanning procedure. Thus, 630 (315

2) source-detector (S-D) pairs were effectively

available and used for image reconstruction. The autocorrelation functions 𝐺1 (𝒓, 𝜏) from
the effective S-D pairs were calculated by the modified NIRFAST software with 𝜏
ranging from 0 to 3.2

10−5 s (50 consecutive 𝜏 values). Reconstruction was conducted

on the same mesh with a pixel basis of 20

20

25 and a 𝜏1 = 8.7

10−6 s. The 𝜏

selection is discussed in the following section (Chapter 4.2.4). The presenting anomaly
was extracted with the full width half-maximum (FWHM) criterion (94) on the
reconstructed DCT image. The averaged BFI and the center location of the reconstructed
anomaly were computed by averaging the BFIs and node coordinates within the anomaly.

Figure 13
Figure 4.1: Procedures converting the breast surface image to a solid breast model. (a) 3D surface geometry of mannequin breast and the reference plane (RP) recorded by 3-D
camera. The lesion mark (red square), three pairs of source marks and the rotation center
mark can be clearly seen. (b) A bottom plane (BP) parallel to the RP was created and a 3D solid breast model was then generated by enclosing the 2-D contour of BP and the 3-D
breast surface.
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Figure 14
Figure 4.2: Alignment of sources and detectors on the surface of solid breast model. (a)
A scanning plane (SP) perpendicular to the breast surface and crossing the optical rays of
sources and detectors was first aligned passing through the first pair of source marks (M1
and M2). (b) Each source or detector path was simplified as a single optical ray
perpendicular to the straight line across the source marks (M1 to M2). The sources and
detectors along the optical rays were then projected onto the surface of solid breast model.
The SP was then rotated around the rotation axis step-by-step with a 3-degree increment
per step for projecting sources and detectors at all scanning steps. (c) The alignment of all
scanned source and detector coordinates.

In order to assess the ability of ncDCT for imaging a tumor inside breast, I conducted
a computer simulation on a female plastic mannequin breast. The surface geometry of the
mannequin breast with source marks of ncDCT were scanned by a commercial 3-D
camera, which was further converted to a solid breast tissue volume using SolidWorks
(Figure 4.1). The scanned source and detector coordinates were then aligned on the
surface of the solid breast model based on two pairs (at first and last scanning steps) of
source marks (Figure 4.2). The probe scanning procedure was simulated by SolidWorks.
Similar to the slab meshing, the solid breast volume was segmented into finite elements
with node distances of 3 and 6 mm in the ROI and surrounding region. A solid volume
mesh [largest dimension (mm): 100 (H)

78 (W)

70 (D)] with total nodes of 14717

was generated for simulations. A spherical tumor with a diameter of 10 mm and a node
distance of 3 mm was then placed at the ROI center and the tumor centroid location was
7 mm beneath the breast surface (Figure 4.3e). For comparisons, we assigned the same
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optical properties and BFI contrast as those used in slab-tissue simulation. The boundary
data were also collected in the same manner over the ROI on the breast surface. Identical
breast-shaped mesh with a pixel basis of 20

20

30 and 𝜏1 = 8.7

10−6 were used

for image reconstruction.

4.2.2 Quantification of Tumor Location and Flow Contrast in the Breast-shaped Tissue
Volume
This simulation used the same tumor model in the breast-shaped mesh with the same
configuration and optical properties as assigned in Chapter 4.2.1 (see Figure 4.3e). The
tumor was placed beneath the surface of the breast-shaped mesh with varied central
depths from 7 mm to 15 mm at 1 mm increment per step. It is noted that breast tumors
with their centroid locations within the sensitive region of diffuse light (i.e., the detected
penetration depth of NIR light is ~1/2 of the S-D separation (65, 67, 101)) were our most
interested study population, since more reliable reconstructions can be generated. At each
depth, the tumor-to-normal flow contrast was increased from 0-fold to 20-fold at 5-fold
increment per step. The reconstructed tumor depth was characterized as the shortest
distance from the reconstructed anomaly center to the breast mesh surface. The
measurement accuracy of ncDCT system was assessed by quantifying the discrepancies
between the reconstructed and assigned values in tumor central location and flow contrast.
To evaluate the noise influence on image reconstruction, I added noise on the subsets
of boundary data collected from the tumor with 10-fold flow contrast throughout all
varied depths. Forty 𝑔2 (𝒓, 𝜏) curves with noises were generated and averaged at each
effective S-D pair for DCT image reconstruction.
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4.2.3 Reconstruction with A Priori Knowledge of Tumor Location and Volume
To improve the reconstruction accuracy of anomaly blood flow contrast, the softconstraint method (94, 102-104) in NIRFAST package was tested in this simulation. A
priori structural information of tumor (i.e., central location and tumor volume) was
included in the inverse mesh by labeling the nodes in the inverse mesh according to the
regions of tumor or surrounding tissues. A regularization matrix L was applied to the
penalty term in the minimization function for DCT inverse problem, which was
equivalent to applying a Laplacian-type filter to minimize variation within each region.
Simulations were done with the spherical anomaly (10-fold flow contrast and diameter =
10 mm) placed at either 7 mm or 15 mm central depth beneath the breast surface and with
or without noise.

4.2.4

Evaluation of Image Reconstruction Accuracy with Different τ Values

Previous DCT studies emphasized assigning a selective delay time 𝜏 to each S-D pair
based on the analytical expression for 𝑔1 (𝒓, 𝜏) (Equation 2.6) which relies on simple
geometry and homogeneous optical properties (60)(59). By contrast, we proposed to use
a

uniform

𝜏

for

flow

contrast

imaging

(37).

From

the

view

of

𝜇𝑎𝑑 (𝜏, 𝒓) = 2𝜇𝑠 ′(𝒓)𝑘20 𝛼𝐷𝐵 (𝒓)𝜏, assigning uniform 𝜏 unifies the 𝜇𝑎𝑑 (𝜏, 𝒓) on the same time
scale such that 𝜏 does not generate extra 𝜇𝑎𝑑 (𝜏, 𝒓) contrast. However, since the accuracy
of the numerical model and computation of Jacobian matrix in NIRFAST software rely
on optical properties (105) (here indicates 𝜇𝑎𝑑 (𝜏, 𝒓)), 𝜏 selection could influence ncDCT
image reconstruction. To evaluate the 𝜏 selection influence, twenty τ values ( 1.0
10−7 ≤

≤ 6.4

10−5 ) from the entire range (generally from 1.0
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10−7 to 1.0

10− 3

s) were used to reconstruct DCT images. With each selected τ value, anomaly (tumor)
was assigned 5-, 10- and 15-fold flow contrasts and the central depth was set at 7 and 10
mm beneath the breast-shaped mesh surface. The reconstruction accuracies in tumor
location and flow contrass were compared.

4.3 Results
4.3.1 ncDCT Recovered an Anomaly inside both Slab-shaped and Breast-shaped Tissue
Volumes with Similar Accuracies
Figure 4.3 illustrates 3-D (Figures 4.3a, 4.3b, 4.3e and 4.3f) and 2-D cross-section
(Figures 4.3c, 4.3d, 4.3g and 4.3h) views of blood flow distributions in the slab-shaped
(top panel) and breast-shaped (bottom panel) tissue volumes, respectively. Figures 4.3a,
4.3e, 4.3c and 4.3g show the originally assigned/simulated anomaly inside tissue volumes
and Figures 4.3b, 4.3f, 4.3d and 4.3h show the reconstructed results for comparisons. To
clearly visualize the anomaly inside the tissue volume, 3-D background meshes were
presented with 30% transparency of their original colors. The reconstructed anomalies
were presented with FWHM thresholds in 3-D images (Figures 4.3b and 4.3f) and
without thresholds in 2-D cross-section views (Figures 4.3d and 4.3h). Table 4.1
summarizes the discrepancies between the assigned and reconstructed anomalies inside
the slap-shaped and breast-shaped tissue volumes. These results indicate that the ncDCT
system can recover the anomaly inside both slap-shaped and breast-shaped tissue
volumes with similar accuracies.
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Table 4.1: Computer simulation results in recovering an anomaly* inside slab-shaped
and breast-shaped volume meshes. Table 1

Anomaly
central depth
(mm) / % error

Anomaly
diameter (mm)
/ % error

Peak flow
contrast (fold)
/ % error

Average
flow contrast
(fold) / % error

Slab-shaped

6.4 / 8.6%

7.2 / 28%

12.8 / 28%

9.3 / 7%

Breast-shaped

6.6 / 5.7%

7.5 / 25%

12.2 / 23%

8.1 / 19%

*A spherical anomaly with a diameter of 10 mm and 10-fold flow contrast was placed at
7 mm beneath the surface of background tissue volumes.

(a)

(b)

(c)

(d)

(f)

(g)

(h)

0.03

(e)

0.09

Figure 4.3: Recovery of anomaly blood flow contrasts inside the slab-shaped and breastshaped volume meshes. A sphere anomaly with a diameter of 10 mm and 10-fold flow
contrast was placed at 7 mm beneath the surface of background tissue volumes. (a) and
(e) show the original assigned anomalies inside the volume meshes with sources and
detectors aligned on the mesh surfaces; (b) and (f) show the reconstructed anomalies with
FWHM thresholds; (c) and (g) show the 2-D cross-section views of original flow contrast
distributions through the anomaly centers; (d) and (h) show the 2-D cross-section views
of reconstructed flow contrast distributions. Figure 15
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4.3.2 Higher Reconstruction Accuracy Achieved when the Anomaly was within the
Sensitive Region of Diffuse Light
The reconstruction results with varied anomaly locations and flow contrasts are
presented in Figure 4.4. The discrepancies (Figure 4.4b) between the reconstructed and
assigned central locations of the anomaly were smaller than the mesh node distance (3
mm) at all depths. The reconstructed anomaly locations were more accurate in the
sensitive region of diffuse light (errors ≤ 0.5 mm at central depths ≤ 10 mm) compared to
those in deeper depths.
Reconstruction errors in peak and average BFI contrast of the anomaly at varied
center location and assigned flow contrasts are displayed in Figure 4.4c. The largest
reconstruction errors in peak and average flow contrasts ranged from 31.4% to -77.0%
and -23.6% to -82.9% respectively through all varied depths and flow contrasts. Similarly,
the reconstructed peak and average BFI contrasts were more accurate in the sensitive
region of diffuse light (peak and average BFI underestimations ≤ 27.8% and 45.3%
respectively at central depths ≤ 10 mm) compared to those in larger depths.
Figures 4.4d and 4.4e demonstrate the linear relationships between the assigned and
reconstructed peak and average BFI contrasts. The relative anomaly flow contrast
changes were well reconstructed from the chosen central depths of 7 mm (peak BFI:
linear regression slope = 1.03, R2 = 0.99, and p < 0.001; average BFI: linear regression
slope = 1.02, R2 = 0.99, and p < 0.001), 10 mm (peak BFI: linear regression slope = 1.01,
R2 = 0.97, and p < 0.01; average BFI: linear regression slope = 1.00, R2 = 0.97, and p <
0.01), 13 mm (peak BFI: linear regression slope = 1.07, R2 = 0.98, and p < 0.01; average
BFI: linear regression slope =1.07, R2 = 0.98, and p < 0.01), and 15 mm (peak BFI: linear
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regression slope = 1.08, R2 = 0.98, and p < 0.01; average BFI: linear regression slope =
1.08, R2 = 0.98, and p < 0.01). The relationships between the assigned and reconstructed
relative anomaly flow contrast changes from other tested depths were similar (results not
shown here).
In total, these results indicate that relatively higher accuracies were achieved when
the entire anomaly was within the sensitive depth of diffuse light. Also, even though the
recovery of anomaly BFI contrasts was not as accurate as its location, the reconstructed
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500
400
300
200
depth 7 mm
depth 10 mm
depth 13 mm
0
depth 15 mm
0
100 200 300 400
relative change of assigned BFI %

100

Figure 4.4: Evaluation of reconstruction accuracy of ncDCT in the breast-shape volume
mesh. (a) and (b) show the center location and deviation of the reconstructed anomaly at
different depths; (c) shows the percentage deviations of anomaly peak and average BFI
contrasts at different depths; (d) and (e) show the linear relationships between the
assigned and reconstructed peak & average BFI contrasts at different depths. Figure 16
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4.3.3 Noise Reduced Anomaly Recovery Accuracy
Figure 4.5 shows the ncDCT image reconstruction results with simulated noise added
to the forward problem. For comparisons, images reconstructed from clean data (no noise)
and noisy data are plotted together. When the anomaly volume was within the sensitive
region of diffuse light (anomaly central depth ≤ 10 mm), the largest discrepancy between
the reconstructed and assigned central locations of the anomaly was 1.2 mm (Figure
4.5b), 0.8 mm greater than that (0.4 mm) without noise. Similarly, the largest
reconstruction errors in peak and average flow contrasts were 33.2% and 31.0% larger
than those reconstructed without noise (Figures 4.5c and 4.5d). Apparently, adding noise
reduced reconstruction accuracies in recovery of the anomaly. However, the major
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Figure 4.5: Noise influence on imaging accuracy of ncDCT. An anomaly was placed
beneath the surface of the breast-shaped mesh with varied central depths from 7 mm to
15 mm. (a) and (b) show the center location and deviation of the anomaly at different
depths, reconstructed with or without noise. (c) and (d) show percentage deviations of
anomaly peak and average BFI contrasts at different depths, reconstructed with or
without noise. Figure 17
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4.3.4 A Priori Knowledge of Anomaly Location and Volume Improved Flow Contrast
Reconstruction
Figure 4.6 demonstrates the improvements in the reconstruction of BFI contrasts
using a priori knowledge of tumor location and volume in DCT image reconstruction.
The top (Figures 4.6a to 4.6e) and bottom (Figures 4.6f to 4.6j) panels show the
reconstructed results when the anomaly is at the central depth of 7 and 15 mm beneath
the surface, respectively. In each panel, image results without/with a priori information
and without/with noise are plotted respectively. The transect plots (Figures 4.6e and 4.6j)
show the BFI distributions across the anomaly. The reconstruction accuracies in BFI
contrasts were significantly improved when a priori knowledge of anomaly structural
information was applied on data with and without noise. The peak/average BFI contrast
errors were only 0.1%/4% (without noise) and 12.3%/12.3% (with noise) respectively
when using a priori structural information for the anomaly located in the sensitivity
region of diffuse light (i.e., at the central location of 7 mm, Figure 4.6e). The BFI
contrast improvement at the deeper central depth of 15 mm was also remarkable (Figure
4.6j).
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Figure 4.6: Comparison of anomaly reconstructions without and with a priori structural
information. The top (a to e) and bottom (f to j) panels show the reconstructed flow
contrast distributions of an anomaly (assigned a 10-fold flow contrast) located at 7 and 15
mm central depths, respectively. (a) and (f) show reconstructed results without the a
priori structural knowledge of the anomaly; (b) and (g) show the reconstructed results
with the a priori structural knowledge; (c) and (h) show the reconstructed results without
the a priori structural knowledge and with noise. (d) and (i) show the reconstructed
results with the a priori knowledge information and with noise. The flow contrast profiles
crossing the yellow lines are shown in (e) and (j). Figure 18

4.3.5 Optimization of τ Improved Imaging Accuracy
Figure 4.7 shows the errors in the reconstructed anomaly locations and BFI contrasts
with different τ selections. The discrepancies (Figure 4.7a) between the reconstructed
and assigned central locations of the anomaly were smaller than the mesh node distance
(3 mm) at all tested anomaly central depths and contrasts. The reconstructed anomaly
locations were more accurate when τ was chosen in the range of 5.1
1.91

10−6 sec to

10−5 sec (between the two vertical lines in Figure 4.7a). Reconstruction errors in

average BFI contrast with varied τ selections are displayed in Figure 4.7b. By choosing
proper τ value, the error in reconstructed average flow contrast inside the anomaly can be
reduced up to 27.6% (i.e., anomaly with 15-fold flow contrast located at 7 mm depth).
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While smaller τ provided more accurate flow contrast reconstruction for anomaly located
shallower, larger τ was more preferable for anomaly located deeper from mesh surface. In
10−6 ≤ 𝜏 ≤ 1.91

general, τ selected from certain range (5.1

10−6 sec) between the

two vertical lines shown in Figure 4.7b can provide more accurate results in flow
contrast and location reconstructions.
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Figure 4.7: Evaluation of reconstruction accuracy of ncDCT with varied τ values based
on meshes with 5-, 10- and 15-fold anomaly flow contrasts, and anomaly centroid located
at 7 mm and 10 mm depths. (a) Shows deviation of the reconstructed anomaly center
locations. Positive/negative values indicate deeper/shallower than original locations. (b)
Shows reconstruction errors in average flow contrasts inside anomalies. Two pairs of
black vertical lines in (a) and (b) are plotted at the same τ values, respectively, indicating
the recommended τ intervals for image reconstruction. Figure 19

4.4 Discussion and Conclusions
In this chapter, computer simulations were used to investigate the origins of flow
reconstruction discrepancies. From the simulations, we observed similar reconstruction
accuracies in blood flow contrasts and tumor central locations with slab-shaped and
breast-shaped boundaries (see Figure 4.3 and Table 4.1), indicating the ability of ncDCT
for reconstructing tumor flow contrast in human breast with irregular geometry. Further
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simulations on breast-shaped geometry evaluated reconstruction accuracies when tumors
had different flow contrasts and located at different depths. The results suggested that the
reconstructed tumor location and flow contrasts were more accurate when the tumor
volume was within the sensitive region of diffuse light (see Figure 4.4). Based on photon
diffuse theory, the penetration depth of diffuse light is ~1/2 of the S-D separation (65, 67,
101). The largest S-D separation of ncDCT was 30 mm, allowing for a penetration depth
up to ~15 mm. As such, it was not surprising that the reconstruction errors increased as
the tumor center located at a depth deeper than 10 mm.
In contrast to the recovery of tumor location, the reconstruction of tumor blood flow
contrasts was more complicated. The reconstructed peak BFIs were overestimated when
the tumor located closer to the breast surface and underestimated when the tumor located
out of the sensitive region of diffuse light (see Figure 4.4c). By contrast, the
reconstructed average BFIs were consistently underestimated. These observations are
similar to those in DOT for reconstruction of tumor absorption contrasts (106, 107). It is
known from the DOT practice that imaging sensitivity is higher at the shallow region
beneath tissue surface (108). Therefore, the reconstructed peak BFI from a single node
close to the tissue surface tends to be overestimated. However, most of the reconstructed
BFIs from the tumor node are prone to be underestimated due to the nature of inverse
problem (109). Since the number of boundary data (S-D pairs) in ncDCT is much smaller
than the unknowns to be solved (i.e., BFIs at all mesh nodes), the inverse problem is
unstable (110), leading to the underestimation (106). In addition, according to the
definition of 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) = 𝜇𝑎 (𝒓) + 𝜇𝑎𝑑 (𝒓, 𝜏), BFI reconstruction errors come from both
“static” and “dynamic” absorption coefficients. Therefore, dynamic flow contrast errors
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may be further enlarged by attributing all reconstruction errors of 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) to dynamic
𝜇𝑎𝑑 (𝒓, 𝜏) while ignoring static errors of 𝜇𝑎 (𝒓).
Similar to our previous findings (37), the relative changes of tumor flow contrasts can
be accurately reconstructed in a large range of flow contrast variations (see Figures 4.4d
and 4.4e). The observed linear relationships with a slope of close to “1” indicate the
ability of ncDCT to capture tumor blood flow changes, which can be potentially used to
longitudinally monitor tumor hemodynamic responses to interventions.
As expected, adding noise reduced the reconstruction accuracies (see Figure 4.5).
However, tumors can still be reconstructed clearly from the boundary data with noise (see
Figure 4.5), indicating the feasibility of ncDCT for in vivo breast tumor detection. More
importantly, adding a priori knowledge of the tumor volume and location improved
significantly reconstruction accuracy (see Figure 4.6), which agrees with previous
observations in DOT (94, 102, 104).
Our previous publication has briefly discussed the selection of τ for image
reconstruction (37). Five different τ values (4

10−7 ≤

≤ 1.9

10−5 s) were selected

for computer simulations, and the results showed little impact on the reconstructed flow
contrast. Further investigation with a broad range of experimental configurations was
conducted in this study. Simulations with extensive τ selections ( 1.0
6.4

10−7 ≤

≤

10−5 ) have been performed to evaluate the influence on flow contrast and location

reconstruction when the tumor was within the sensitive region of diffuse light. Different τ
selections have smaller influence in the tumor location recovery compared with the flow
contrast recovery. However, within the same range of τ selection (5.1
1.91

10−6 ≤

≤

10−5 ) the reconstruction accuracies in both flow contrast and tumor central
62

location reconstructions are higher than with the other τ values. So we propose to select
the range 5.1

10−6 ≤

≤ 1.91

10−5 for future ncDCT image reconstruction.

In conclusion, computer simulations based on different boundary geometries were
performed to demonstrate the imaging capability of the novel ncDCT system on breast
tumor detection. Results suggested that relatively high ncDCT image reconstruction
accuracy can be achieved when the entire tumor was within the sensitive region of diffuse
light. Image reconstruction with a priori knowledge of the tumor volume and location can
significantly improve the accuracy in tumor blood flow contrast reconstruction. The
optimized range of τ selection ( 5.1

10−6 ≤

≤ 1.91

10−5 ) was provided to

reconstruct ncDCT images with higher accuracies. Based on the computer simulation
results, future development in instrumentation should increase the effective measurement
pairs to reduce the underestimation nature of the inverse problem. Measurements from
deep tissue are especially helpful to improve the image reconstruction accuracy. Depth
correction algorithms should be integrated for ncDCT image reconstruction (i.e., increase
the weights to information obtained from elements located deep inside mesh) such that
tumor location recovery is more accurate even though the tumor was outside the sensitive
region of diffusive light.
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CHAPTER 5 NCDCT OF HUMAN BREAST TUMORS

5.1 Introduction
The autonomic growth and spread of malignant tumors are dependent on increased
angiogenesis arising from the increased metabolic demand (111). Since functional
alternations in tumors often appear earlier than detectable morphological changes,
functional imaging of tumor hemodynamics and metabolism is a new strategy for early
cancer diagnosis (112). Previous studies using different imaging modalities have found
significant tumor-to-normal blood flow contrast in carcinomas, e.g., up to 12-fold
contrast was found in post-menopausal women by PET (14, 113) and 3-fold contrast in
flow velocity was also found by Doppler Ultrasound (114). Near-infrared (NIR) diffuse
optical technologies provide a noninvasive and relatively inexpensive tool for functional
imaging of tumor hemodynamics in deep microvasculature up to several centimeters (5355, 115). The most commonly used NIR diffuse optical spectroscopy/tomography
(DOS/DOT) can quantify total hemoglobin concentration (THC) and blood oxygen
saturation (StO2) in tumors (116, 117). DOS/DOT has been used over several decades to
detect oxygenation alternations in breast tumors (32-36). For example, THC was found
up to 2-fold higher in malignant lesions than nearby healthy tissues (117). More recently,
a novel NIR diffuse correlation spectroscopy (DCS) technique has also been developed
for direct measurement of blood flow index (BFI) in deep tissues (37). A few pilot studies
of breast tumors using DCS have found increased blood flow inside the tumor in contrast
to surrounding normal tissues (i.e., 2- to 10-fold flow contrasts) (53, 55). Real-time
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monitoring of breast tumor blood flow response to neoadjuvant chemotherapy also
demonstrated the potential of DCS for assessing cancer therapies (53, 56, 57).
Our group has recently developed a novel noncontact DCT (ncDCT) system enabling
3-D imaging of deep tissue blood flow distribution without contacting the tissue (37, 89,
92). The imaging theory (Chapter 2), instrumentation of ncDCT system (Chapter 3) and
validation work including computer simulations and phantom experiments were
described (Chapters 3 and 4) in previous chapters. In this chapter, I report the first 3-D
blood flow contrast imaging of human breast tumors using the noninvasive, noncontact
diffuse correlation tomographic technique.

5.2 Methods
5.2.1 Subjects
Twenty-eight female patients with breast tumors were recruited from University of
Kentucky Comprehensive Breast Care Center with signed informed consent approved by
the University of Kentucky Institution Review Board. According to our ncDCT system
design and measurement protocol, patients with lesions located no deeper than 2 cm
(central to breast surface, measured by ultrasound imaging) and from 9 o’clock to 3
o’clock on the breast were recruited. There were no wound on patients’ breasts and all the
patients had their scheduled biopsy procedures following the optical measurements. The
biopsy results showed 7 patients had malignant tumors and 21 patients had benign lesions.
The average age of the patients was 47.6 ±16.3 years (see Table 5.1).
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9:00

3:00 9:00

3:00

Figure 5.1: Schematic diagram (a) and ultrasound image (b) of breast lesion locations
(118). Figure 20

5.2.2 Experimental Protocol
The patient was asked to lie in a supine position or on her side (with pillow support)
according to the lesion location. The tumor lesion inside breast was determined by
radiologists using ultrasound imaging prior to the optical measurement and marks were
made on breast surface with mark pens. The tumor mass margin along the radio direction
was also marked on the ultrasound images, which was used to compare with our
reconstructed flow contrast images.
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3-D Camera
Scanning - Breast
(5 min)

ncDCT Scanning
(25 min)

Ultrasound
Imaging
(5 min)

Patient Measurement Takes ~ 40 min

Tissue µ a µ s’
Measurement
with Imagent
(5 min)

3-D Camera
Scanning Reference Plane
(5min)

Figure 5.2: Flow chart of experimental protocols. Figure 21

The ncDCT probe was then aligned perpendicularly on top of the marked lesion
region, with two sources evenly distributed on two sides of the lesion along the radio
direction. Light intensities injected to breast tissue were adjusted to meet American
National Standards Institute standards for laser safety usage (119). The ncDCT probe was
then driven by a step motor to scan rotationally around the breast nipple over the region
of breast tumor. The scanning procedures were similar to those described previously
(Chapter 4.1.1). Briefly, multiple rotational scanning steps were taken to cover the tumor
bearing region in the breast, with a 3-degree increment per step. For each patient, the
number of scanning steps may vary depending on the tumor size and lesion location
relative to the breast surface. Forty 𝑔2 (𝒓, 𝜏) curves were collected from each sourcedetector (S-D) pair for each patient. Two source pairs at the beginning and ending steps
of scanning procedure and the rotation center were visually marked on the breast surface
as references for the alignment of sources and detectors on the surface mesh. The surface
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geometry of the breast with the source and rotation center marks was then recorded by a
commercial 3-D camera for image reconstruction. Following the ncDCT measurement,
the Imagent was used to measure 𝜇𝑠′ and 𝜇𝑎 of the breast tissue at three different locations
(Chapter 3.3.3) (71). The averaged 𝜇𝑠′ and 𝜇𝑎 over the multiple sites were used as initial
inputs for flow image reconstruction. After the patient leaves the measurement bed,
another photo of the ncDCT probe and the reference plane was taken for the alignment of
the scanned source and detector coordinates onto the breast-shaped mesh. The total
measurement time on patient is around 40 minutes (Figure 5.2).

5.2.3 Image Reconstruction
The solid breast mesh of the patient was created in the same way as that of plastic
mannequin breast (Chapter 4.1.1). The node distance was 3 mm in the ROI and 6 mm in
the surrounding region. Boundary BFIs on the breast mesh surface were then extracted by
fitting the measured 𝑔2 (𝒓, 𝜏) curves from effective S-D pairs. These boundary BFI data
were then calibrated to the BFIs collected at the first scanning step where the tissue
underneath the probe was outside the tumor region and thus assumed to be homogeneous
and healthy. The calibrated boundary data were finally used for DCT image
reconstruction.
Noise Influence Evaluation. Apart from the noises mentioned in computer
simulations originated from electronics and optics, there were other noises in the breast
tissue measurements. Those additional noises include physiological noises such as
respiration and heart beating, motion artifacts such as patients’ body gesture changes and
tumor heterogeneity caused noise during light propagation in tissues. In order to evaluate
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the noise influence, the coefficients of variation (Cv) in extracted boundary BFIs from
breast tissues and liquid phantoms were compared:
𝑠𝑡𝑑 (𝐵𝐹𝐼)

𝐶𝑣 = 𝑚𝑒𝑎𝑛 (𝐵𝐹𝐼)

(5.1)

For patient measurements, the Cv of boundary BFIs from each scanning step were
calculated according to Equation 5.1. According to the protocol for breast tissue
measurements, there were 40 optical measurements per step from each source-detector
pair. For liquid phantom measurements, same measurement procedures were performed
following the in vivo measurements, with same optical properties and detected light
intensities.
The boundary BFI data from one patient with invasive ductal carcinoma (Patient No.
19) was analyzed as an example. This patient kept her body position well during the
scanning of ncDCT. Figure 5.3a shows the mean values and standard deviations of the
normalized boundary BFIs/flow indices obtained at one single S-D pair (2 cm S-D
separation) in the breast tissue (over tumor region) and phantom solution. Figure 5.3b
plots the Cv values at all steps according to Figure 5.3a. The averaged Cv values for the
breast tissue and phantom measurements were 0.105 ± 0.017 and 0.089 ± 0.004,
respectively. Significant differences were found between the two groups of Cv values (p
= 0.005). Large variations observed from the patient were likely due to the physiological
noises in in vivo measurements.

69

(a)

(b)

1.4

0.16

normalized BFI

1.3

Coefficient of Variation

breast tissue
phantom

1.2
1.1
1
0.9
0.8
0.7

0

2

4

6

8

10

12

14

0.14

0.12

0.1

0.08

0.06

16

Scan Step

breast tissue
phantom

0

2

4

6

8

10

12

14

16

Scan Step

Figure 5.3: The effect of additional noises on in vivo breast tissue measurement from one
patient analysis. (a) Normalized boundary BFI measured on breast and phantom solution
by recording one source-detector measurement pair through 15 scanning steps. (b) The
coefficients of variation derived from (a). Figure 22

The Cv values from other patients’ measurement data may vary due to the stability of
patients’ body positions during measurements. Therefore, the data with obvious motion
artifacts (with large Cv values) were excluded from the image reconstruction.

5.3 Results
5.3.1 Representative Individual Results
Representative 3-D reconstructed images from two patients with malignant cancers
and two subjects with benign lesions are shown in Figures 5.4-5.7.
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Figure 23
Figure 5.4: Clinical example of ncDCT imaging result from case 1. (a) Patient No. 16
ultrasound image taken from radio direction shows a 10.2 × 6.65 mm2 oval mass (inside
the yellow dashed circle) with circumscribed margins parallel to the skin. The mass
center is located at 19.2 mm beneath the skin surface. A core biopsy revealed a ductal
papilloma with low-grade ductal adenocarcinoma in situ. (b) Shows the reconstructed 3D tumor blood flow contrasts with FWHM threshold (pink mass). The red and yellow
dots indicate scanned source and detector locations. (c) Shows the cross-section view,
which is displayed in (b), through the reconstructed tumor center. The reconstructed
tumor center is 10.8 mm deep. S1 and S3 are one pair of projected source locations at one
scanning step. (a) was taken with ultrasound transducer aligned from S1 to S2.

Case 1 (Patient No.16): Ductal Papilloma with Low-grade Ductal Adenocarcinoma in
situ (malignant)

The first case (Patient No. 16) was a 59-year-old female who had ductal papilloma
and low-grade adenocarcinoma in situ. According to the ultrasound imaging (Figure
5.4a), the lesion with the dimension of 10.2 × 6.65 mm2 was located at 19.2 mm beneath
the skin surface. The dimension of the reconstructed tumor by ncDCT with the full width
half-maximum (FWHM) threshold was approximately 15.1 × 5.8 mm2 (Figure 5.4c),
which matched ultrasound image. However, the reconstructed tumor central location was
10.8 mm beneath the breast surface, which differed from the ultrasound image result
(19.2 mm). The 2-D cross-section view shown in Figure 5.4c was cut along the radio
direction of scanning and through the tumor center and breast nipple (see extracted cross71

section in Figure 5.4b). The peak and average tumor blood flow contrasts were 8.3-fold
and 5.9-fold, respectively. Note that measurement noise caused some artifacts with
𝜇𝑎𝑡𝑜𝑡𝑎𝑙 (𝒓, 𝜏) lower than static 𝜇𝑎 (𝑟) in the region bordering the reconstructed tumor,
leading to some negative flow values.
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(c)
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16.8
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s1

s2
12.4

-3.6

Figure 5.5: Clinical example of ncDCT imaging result from case 2. (a) Patient No. 26
ultrasound image taken from radio direction shows a 8.5 × 3.5 mm2 mass (inside the
yellow dashed circle), located at 13.3 mm beneath the skin surface. A core biopsy
revealed atypical ductal hyperplasia and low-grade carcinoma in situ. (b) Shows the
reconstructed 3-D tumor blood flow contrasts with FWHM threshold (big pink mass is
the reconstructed tumor, the other two masses are artifacts). The red dots indicate
scanned source locations. (c) Shows the cross-section view through the reconstructed
tumor center. The reconstructed tumor center is 12.4 mm deep. Figure 24

Case 2 (Patient No. 26): Atypical Ductal Hyperplasia and Low Grade Carcinoma
in situ (maligant)
The second case (Patient No. 26) was a 49-year-old female who had an atypical
ductal hyperplasia and low-grade carcinoma in situ. Ultrasound images (Figure 5.5a)
show that the lesion centroid was located at 13.3 mm beneath the skin surface with the
dimension of 8.5 × 3.5 mm2. Our ncDCT imaging results show a clear large tumor lesion
with two small suspicious artificial anomalies (Figure 5.5b). The dimension of the
reconstructed large tumor was approximately 12.3 × 5.1 mm2 (Figure 5.5c) and its
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central depth was 12.4 mm beneath the breast surface, which fairly matched the
ultrasound imaging result. The peak and average blood flow contrasts were 14.0-fold and
10.6-fold, respectively. Artifacts with negative flow values were also observed in the
region bordering the reconstructed tumor.

(a)

(b)

(c)

8.3

Figure 5.6: Clinical example of ncDCT imaging result from case 3. (a) Patient No. 22
ultrasound image taken from radio direction shows a 8.3 × 7.6 mm2 mass (inside the
yellow dashed circle), located at 10.0 mm beneath the skin surface. A core biopsy
revealed a lymphocytic lymphoma. (b) Shows the reconstructed 3-D tumor blood flow
contrasts with FWHM threshold (pink mass). The backgrounds are presented with 30%
transparency of the original color clarity. (c) Shows the cross-section view through the
reconstructed tumor center. The reconstructed tumor center is 8.3 mm deep. Figure 25

Case 3 (Patient No. 22): Lymphocytic Lymphoma (benign)
The third case (Patient No. 22) was a 61-year-old female who had lymphocytic
lymphoma. According to the ultrasound imaging (Figure 5.6a), the lesion with the
dimension of 8.3 × 7.6 mm2 was located at 10.0 mm beneath the skin surface. The
dimension of the reconstructed tumor with FWHM threshold was approximately 4.5 ×
10.5 mm2 (Figure 5.6b) and its central depth was 8.3 mm beneath the breast surface
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(Figure 5.6c), which matched ultrasound imaging result. The peak and average tumor
blood flow contrasts were 6.5- and 4.9-fold, respectively.

(a)

(b)

(c)

6.0

Figure 5.7: Clinical example of ncDCT imaging result from case 4. (a) Patient No. 20
ultrasound image taken from radio direction shows a 10.4 × 2 mm2 mass (inside the
yellow dashed circle), located at 5.8 mm beneath the skin surface. A core biopsy revealed
a fibroadenoma, no atypical features identified. (b) Shows the reconstructed 3-D tumor
blood flow contrasts with FWHM threshold (pink mass). (c) Shows the cross-section
view through the reconstructed tumor center. The reconstructed tumor center is 6.0 mm
deep. Figure 26

Case 4 (Patient No. 20): Fibroadenoma (benign)
The fourth case (Patient No. 20) was a 24-year-old female who had fibroadenoma
without atypical features. According to the ultrasound imaging (Figure 5.7a), the lesion
with the dimension of 10.4 × 2.0 mm2 was located at 5.8 mm beneath the skin surface.
The dimension of the reconstructed tumor was approximately 7.1 × 2.6 mm2 (Figure
5.7b) and its central depth was 6.0 mm beneath the breast surface (Figure 5.6c), which
matched ultrasound image. The peak and average tumor blood flow contrasts were 13.3fold and 8.6-fold, respectively. Artifacts with negative flow values were observed in the
region bordering the reconstructed tumor.
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5.3.2 Group Results
Table 5.1 summarized group imaging results from in vivo breast tumor measurements.
Higher tumor-to-normal blood flow contrasts were observed in the majority of patients
measured by our ncDCT system (18 out of 28). The peak/average tumor-to-normal blood
flow contrasts, the reconstructed tumor location and dimension were quantified, using the
same methods described in Chapter 4.
Reconstructed tumor depths and dimensions matched ultrasound images well when
the tumors were within the sensitive region of diffuse light (depth of ~ 1.5 cm). For the
benign group with observed blood flow contrasts (n = 14), the averaged blood flow
contrasts in the reconstructed tumor regions were 18.0 ± 7.0 (peak flow) and 12.6 ± 4.7
(mean flow) folds, while the corresponding blood flow contrasts in the malignant group
(n = 4) were 16.0 ± 6.1 (peak flow) and 10.6 ± 3.3 folds (mean flow). No significant
difference was found in blood flow contrasts between the two groups.
Tumor-to-normal blood flow contrasts were not observed in some patients’
reconstruction results. Among those cases, three patients’ data was contaminated by
motion artifacts, one patients’ lesion region was not able to be covered completely by
ncDCT probe (patient No. 5, lesion was 55 mm long located beneath the nipple), and
three patients’ data collection procedures were normal. The lesion types for three patients
with smooth measurements were non-proliferative fibrocystic changes (patient No. 3, 8.7
mm dimension, 12.7 mm central to surface depth), duct ectasia (patient No. 6, 3.5 mm
dimension, 11.6 mm depth) and breast tissue with no significant pathologic abnormality
(patient No. 28, 9.9 mm × 2.4 mm dimension, 8.1 mm depth). In addition, three patients’
reconstruction results were excluded from image reconstruction since the measurement
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procedures were incorrect (n = 2) and the measurement was stopped due to the instrument
malfunction (n = 1).

Table 5.1: Group imaging results from in vivo breast tumor measurements.Table 2
Tumor biopsy results
No.

Race

Age
Type

Description

1
2

W
W

44
46

B
B

3

W

36

B

4

W

60

B

fibroadenoma
intraductal papilloma
non-proliferative fibrocystic
changes
complex fibroadenoma

6

W

57

B

duct ectasia

9

W

22

B

10
11
12
13
15

B
B
B
W
W

30
71
27
55
29

B
B
B
B
B

17

W

63

B

18

B

41

B

20

B

24

B

21

W

47

B

22

W

61

B

fibroadenoma
proliferative fibrocystic
features
lymphocytic lymphoma

23

W

62

B

stromal fibrosis

24

H

20

B

25

W

44

B

W

40

B

27

fibroadenoma with usual
ductal hyperplasia
fibroadenoma
intraductal papilloma
fibroadenoma
fat necrosis
cellular fibroadenoma
intraductal papillomas with
atypical ductal hyperplasia
nodular adenosis with
associated microcalcification

fibroadenoma with myxoid
stroma
cellular fibroadenoma, cannot
exclude benign phyllodes
proliferative fibrocystic
change with prominent cyst
formation and extensive
papillary apocrine metaplasia
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ncDCT imaging
Peak
flow
/ fold

Mean
flow
/ fold

Depth
/ mm

US
imaging
depth
/ mm

Excluded (reason A)
Excluded (Reason A)
No contrast observed
(Reason C)
Excluded (Reason B)
No contrast observed
(Reason C)

NA
20.3

20.2

14.3

9.7

12.8

19.1
11.8
17.6
18.3
15.7

13.2
8.5
13.6
13.6
10.3

9.1
9.2
13.0
6.2
10.2

14.1
11.5
10.3
5.5
9.5

25.1

17.2

11.2

27.0

18.9

12.6

13.8

15.0

13.3

8.6

6.0

5.8

17.3

12.1

12.3

19.0

6.5
4.9
8.3
No contrast observed
(reason B)

10.0

26.7

17.9

5.9

12.2

8.2

6.6

10.6

14.8

32.8

22.4

9.7

11.5

12.7
12.0
11.6

22.2

Table 5.1 (continued)
28

B

Benign
tumor
summary

breast tissue with no
No contrast observed
64
B
significant pathologic
(Reason C)
abnormality
Total number of reconstructed tumors / measured: 14 / 21
Peak flow contrast: 18.0 ±7.1fold
Mean flow contrast: 12.6 ±4.7 fold

5

H

32

M

7

W

71

M

8

W

63

M

14

W

73

M

16

B

59

M

19

W

54

M

26

W

49

M

infiltrating moderately to
poorly differentiated ductal
adenocarcinoma
invasive moderately
differentiated ductal
carcinoma
intracystic/encysted papillary
carcinoma in situ
invasive poorly differentiated
ductal adenocarcinoma
ductal papilloma with lowgrade ductal adenocarcinoma
in situ
invasive ductual carcinoma
atypical ductal hyperplasia
and low grade carcinoma in
situ

8.1

No contrast observed
(Reason A)

20.0

No contrast observed
(Reason B)

10.0

No contrast observed
(Reason B)

10.0

21.5

12.4

7.6

19.4

8.3

5.9

10.8

19.2

20.1

13.4

15.9

20.0

14.0

10.6

12.4

13.3

Malignant Total number of reconstructed tumors / measured: 4 / 7
Peak flow contrast: 16.0 ±6.1fold
tumor
summary Mean flow contrast: 10.6 ±3.3 fold
W: White; H: Hispanic; B: Black
M: Malignant; B: Benign
US: Ultrasound
Reasons for no tumor flow contrasts : A – lesion region could not be covered completely
by ncDCT probe; B – data was contaminated by motion artifacts (i.e., body gesture
changed and coughed); C – data collection was normal, however, no flow contrast was
observed.
Excluded reasons: A – measurement procedure was invalid (i.e., source and detector
scanning coordinates couldn’t be correctly aligned on the mesh); B – measurement was
stopped due to the instrument malfunction.
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5.4 Discussion and Conclusions
Since increased angiogenesis in breast tumor is commonly associated with blood flow
increase, imaging of blood flow distribution in breast tissue is of great importance for
tumor detection (111). Previous phantom experiment and computer simulations
(Chapters 3 and 4) have demonstrated the feasibility of applying ncDCT system for
breast tumor flow contrast imaging. The remaining challenge lies in handling potential
problems arising from the in vivo measurements.
In this chapter, preliminary study of human breast tumor imaging with ncDCT system
was performed. Higher blood flow contrasts in the tumor regions compared to the
surrounding tissues were observed in most of measured breast tumors. In reconstructed
ncDCT images with higher blood flow contrasts, the tumor positions on the x-y plane
agreed well with ultrasound imaging results (see examples in Figures 5.4b-5.7b). The
reconstructed tumor central depth matched the ultrasound image when tumors were
located within the sensitive depth of diffuse light (see examples in Figures 5.5c-5.7c).
For some patients, the reconstructed tumor central depths were shallower than ultrasound
imaging result (see example in Figures 5.4c). These were likely due to the fact that
tumors were deeper than the depth where diffuse light cannot reach with our current
ncDCT system.
It has been demonstrated by computer simulations (Chapter 4.2.4) that a prior
knowledge of tumor location and volume can improve image reconstruction accuracy.
However, due to the difficulty of co-registering the 2-D ultrasound image and 3-D
ncDCT image, it was not possible in this study to apply the a priori structural knowledge
of tumor for improving the accuracy of image reconstruction in patients. Future study
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may utilize 3-D anatomical imaging modalities such as MRI or CT to obtain accurate
priori structural information of the tumor.
The averaged mean values of tumor-to-normal blood flow contrasts for two groups of
breast tumors were 10.6 ± 3.3 -fold (malignant) and 12.6 ± 4.7 -fold (benign). The results
were comparable to previously reported flow contrasts of 2- to 10-fold in breast tumors
detected by DCS (53, 55). It should be noted that the tumor flow contrasts quantified
previously by DCS may be underestimated due to the partial volume effect by the healthy
tissues surrounding the tumor. In addition, the potential crosstalk between 𝜇𝑎 , 𝜇𝑠′ and BFI
may also result in over- or under-estimation of blood flow contrasts in both DCS and
ncDCT (67, 83). According to the definition of 𝜇𝑎𝑡𝑜𝑡𝑎𝑙 , 𝜇𝑎 , 𝜇𝑠′ and 𝛼𝐷𝐵 , variations cannot
be completely separated unless they are independently measured. As previous computer
simulations suggested ~250% variation in 𝜇𝑠′ distribution may cause ~297% variation in
BFI reconstruction, while 200 to 300% variations in 𝜇𝑎 may cause 11.5% to 26%
variations in BFI reconstruction (Chapter 3.3.2). So when assuming homogeneous
optical properties over the entire breast, the realistic heterogeneous optical properties
(mainly due to 𝜇𝑠′ ) across the tumor can generate errors in tumor BFI contrasts. To
overcome this limitation, a separate instrument enabling 3-D imaging of 𝜇𝑎 and 𝜇𝑠′
distributions in the breast is needed (e.g., a frequency-domain or time-resolved DOT (32,
120-122)).
We didn’t find difference in the reconstructed blood flow contrasts between the
benign and malignant breast tumors. Since the number of reconstructed images from two
groups of patients was small (n = 14 for benign and n = 4 for carcinoma), the extracted
blood flow contrasts may not be generalizable to two groups of patient populations.
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Furthermore, some studies also showed similar densities of microvasculature between the
low grade breast carcinomas and benign lesions (123), which might result in the overlap
of blood flow contrasts between malignant tumors and benign lesions. In addition,
measurement and reconstruction errors as mentioned earlier may cause difficulty in
distinguishing different tumor types. For example, the crosstalk between the optical
properties (mainly due to 𝜇𝑠′ ) and BFI may induce errors in the reconstructed tumor-tonormal blood flow contrasts. Tumors located at varying depths may lead to certain
amount of over- or under-estimations in BFI reconstruction.
In the future study, we should optimize the imaging system and increase patient
number to investigate the possibility of using ncDCT for characterization/classification of
breast tumors. Overall, the current study demonstrated the potential of ncDCT system to
be used for imaging blood flow distributions in soft and vulnerable tissues without
distorting tissue hemodynamics.
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CHAPTER 6 OPTICAL FIBER MODE OPTIMIZATION FOR BETTER
SIGNAL-TO-NOISE RATIO (SNR)

6.1 Introduction
As described in Chapter 2, NIR light has been recently employed to noninvasively
measure rBF in deep tissues, which is referred to as NIR DCS (38, 41, 54, 58, 65, 75-77,
124) or diffusing wave spectroscopy (DWS) (82, 125, 126). Further development of
DCS technology includes ncDCT for 3-D blood flow imaging (Chapters 3-5) and a dualwavelength DCS flow-oximeter (41, 46, 67, 78, 124, 127), which can simultaneously
measure rBF and oxygenation variations. High SNR is crucial when applying DCS
technologies in study of human tissues where the detected signals are usually very weak
(41, 46, 54, 67, 75-78, 92, 127, 128). In this chapter, I report a study exploring the use of
different types of detector fibers to experimentally compare/improve the SNRs of DCS
flow-oximeter measurements (129).
When using DCS to detect tissue blood flow, a pair of source and detector fibers is
usually placed along the tissue surface. Previous studies have used either single-mode (40,
41, 53, 60, 75, 76, 92, 124, 127, 130) or few-mode (131-134) fibers separately for DCS
flow detections. A single-mode fiber is an optical waveguide whose very small core
radius is comparable with the wavelength of the transported light (131, 135). Light
intensity detected by the single-mode fiber, however, is low due to the fact that only the
fundamental mode of light can be transported. By contrast, few-mode fibers allow a few
higher order modes of light to be guided through the fiber along with the fundamental
mode. Enlarging the fiber diameter and numerical aperture (NA) with few-mode fibers to
cover multiple speckles increases the detected signal intensity, thus improving SNR.
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Conversely, the multiple speckles detected by the few-mode fibers are uncorrelated and
decrease the coherence factor (β) in a proportional fashion (131-134). As a result, the
autocorrelation function curve becomes flatter which may reduce the sensitivity of DCS
flow measurements (60, 136). The detected light intensity can be further increased using
multi-mode fibers with a large core diameter (e.g., 1 mm), although the autocorrelation
function may not be detectable due to very low value of β (i.e., the autocorrelation
function curve becomes a straight line) (135, 137).
Dual-wavelength DCS flow-oximeter was developed by including a second laser to
the DCS device, which enables the extraction of multiple hemodynamic variables
including rBF and changes in oxy-hemoglobin concentration (∆[HbO2]) and deoxyhemoglobin concentration (∆[Hb]). As mentioned earlier, few-mode and multi-mode
fibers collect more photons than single-mode fibers which leads to the following
hypothesis. Increased light intensities measured at two wavelengths by few-mode or
multi-mode fibers should improve the SNRs in measurements of light intensity as well as
tissue blood oxygenation.
In this chapter, three fibers with different modes (i.e., single-mode, few-mode or
multi-mode) were examined in tissue-like liquid phantoms with varied optical properties
and in human forearm muscles during arterial cuff occlusion. The SNRs of the measured
variables were calculated and compared to aid in the selection of fiber(s) for the
improvement of DCS flow-oximeter measurements.
The work reported in this chapter has been published (129) and reprint permission for
this dissertation has been granted by the publisher.
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6.2 Methods and Materials
6.2.1 DCS Flow-oximeter
Flow Measurements. DCS flow indices were quantified by a dual-wavelength DCS
flow-oximeter with two CW coherent laser sources at 785 and 853 nm (100 mw,
Crystalaser, Inc., NV) (46). The coherence length for both lasers was longer than 5
meters. The two DCS sources emitted NIR light alternately into the tissue via two multimode optical fibers with a core diameter of 200 µm (WF200/220/245, Ceramoptec, MA)
bundled at the same location on the phantom/tissue surface. Three detector fibers,
including a single-mode fiber with a core diameter of 4.3 µm (SM600, Fibercore, CA), a
6-mode fiber with a core diameter of 4.5 µm (SM980, Fibercore, CA) and a multi-mode
fiber with a core diameter of 1 mm, were confined by a foam pad at an equal distance of
2.5 cm from the two source fiber bundle (Figure 6.1). These detector fibers were
connected respectively to three single-photon-counting APDs (PerkinElmer Inc., Canada)
inside the DCS device. The outputs of APDs were sent to a 4-channel autocorrelator
board yielding normalized light intensity temporal autocorrelation functions 𝑔2 (𝒓, 𝜏). As
described in DCS theory section (Chapter 2.3), by fitting the analytical expression of
𝑔2 (𝒓, 𝜏) with the 𝑔2 (𝒓, 𝜏) from measurement, the blood flow index αDB and coherence
factor β are extracted simultaneously.
Optical Property Measurements. DCS for flow measurement needs only one
wavelength of light source. Adding a second laser to the DCS device allows for
simultaneous measurements of tissue optical properties. Photons emitted by lasers are
scattered and/or absorbed when they travel through the tissue from the source to detector,
leading to light intensity reductions in detected wavelengths. Similar to CW NIRS, the
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relative change in the tissue absorption coefficient (∆μa) can be derived from the light
intensity changes measured at the two wavelengths (138). Variations of ∆[HbO2] and
∆[Hb] relative to their baseline values (determined before physiological changes) can be
determined from the measured ∆μa at two wavelengths, using the modified Beer-Lambert
Law (73),
∆[HbO2 ] = 𝜀
∆[Hb] =

Here ∆𝜇𝑎 (𝜆) =

𝜀𝐻𝑏 (𝜆1 )∆𝜇𝑎 (𝜆2 )−𝜀𝐻𝑏 (𝜆2 )∆𝜇𝑎 (𝜆1 )
𝐻𝑏 (𝜆1 )𝜀𝐻𝑏𝑂2 (𝜆2 )−𝜀𝐻𝑏𝑂2 (𝜆1 )𝜀𝐻𝑏 (𝜆2 )

𝜀𝐻𝑏𝑂2 (𝜆2 )∆𝜇𝑎 (𝜆1 )−𝜀𝐻𝑏𝑂2 (𝜆1 )∆𝜇𝑎 (𝜆2 )
𝜀𝐻𝑏 (𝜆1 )𝜀𝐻𝑏𝑂2 (𝜆2 )−𝜀𝐻𝑏𝑂2 (𝜆1 )𝜀𝐻𝑏 (𝜆2 )

,

.

(6.1)

(𝐼𝜆𝐵 ⁄𝐼𝜆𝑇 ) /(𝑑DP λ ) , 𝜀𝐻𝑏𝑂2 (𝜆) and 𝜀𝐻𝑏 (𝜆) are the extinction

coefficients of oxyhemoglobin and deoxyhemoglobin. 𝐼𝜆𝐵 and 𝐼𝜆𝑇 are the measured light
intensities at the baseline and time T, respectively. The differential path length factor
(DP λ ) denotes the ratio of the mean photon path length to the distance (𝑑) between the
source and detector pair.

6.2.2 Optical Fiber Modes
For an optical fiber the number of guided modes depends on the core radius (a),
relative refractive-index difference, and operating wavelength (λ). The relation between
the properties of a given dielectric optical waveguide (fiber) and guided waves (number
of modes) can be described by introducing a normalized frequency V (135):
𝑉=

2𝜋𝑎
𝜆

√𝑛12 −𝑛22

(6.2)

Here n1 and n2 are the refractive indices of fiber core and cladding, respectively. The
square root of (n12 - n22) is defined as numerical aperture NA. When V is smaller than the
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critical cutoff frequency VC (e.g., 2.405 for a step-index fiber whose refractive index is
constant within the fiber core), only the fundamental mode LP01 can be guided through
the fiber. Notice that a single-mode fiber can transmit two independent orthogonally
polarized waves; the fiber is actually “bimodal” (135). The operating wavelength
corresponding to VC is called the cutoff wavelength (λC). When the value of V is larger
than VC, the fiber can guide a few higher-order modes along with the fundamental mode;
it becomes a few-mode fiber. The propagating vector modes, i.e., the transverse electric
mode (TE), transverse magnetic mode (TM), or hybrid mode, can be determined by the
following three steps: (1) calculating the V value based on the fiber property using
Equation 6.2; (2) using the V value to obtain transported linear polarized (LP) modes
corresponding from literature values (139) where the LP modes are the eigen-modes of
guided conventional modes (i.e., TE, TM, hybrid mode) and each of them has designation
of conventional modes (wave modes) (137); (3) determining the guided wave modes
according to the compositions of different LP modes.
We used three detector fibers for photon collection in our experiments. According to
the method described above, the single-mode fiber (SM600) has a λC of ~600 nm, NA
between 0.1 and 0.14, and fiber core diameter of ~4.3 μm which guides only two
orthogonal polarization modes of light at the two operating wavelengths of 785 and 853
nm (135). The few-mode fiber (SM980) has a λC of ~970 nm, NA between 0.17 and 0.19,
and fiber core diameter of ~4.5 μm which guides six modes of light operating at both 785
and 853 nm wavelengths. In Chapter 6.3.1 we experimentally checked and confirmed
these calculated numbers of guided modes using measured values of 1/β. The third fiber
used is a regular multi-mode fiber with a diameter of 1 mm.
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6.2.3 Phantom Experiments
Distilled water, India ink and Intralipid were utilized in constructing liquid phantoms
which provided a homogeneous tissue model (see details in Chapter 3.4.1) (41, 67, 92).
An optical probe shown in Figure 6.1 was placed on the surface of the liquid phantom
solution contained inside a glass aquarium. A custom-made probe holder attached to a lab
stand held the probe at the center of solution to simulate a semi-infinite geometry. Room
light was turned off during experiments. In order to test the SNR at different levels of
light intensity, a titration protocol of gradually varying µa was applied. The optical
property of liquid phantom was set initially at µa = 0.05 cm-1 and µs’ = 8 cm-1 at 853 nm.
The corresponding µa and µs’ for the second wavelength (785 nm) at each titration step
were calculated according to the volumes of water, India ink and Intralipid in the
phantom solution (67). The µa (853 nm) was then gradually increased up to 0.15 cm-1 at a
step size of 0.025 cm-1 by adding ink to the liquid phantom while µs’ was kept constant
(without changing the concentration of Intralipid). Optical measurements were taken by
the DCS flow-oximeter for 10 minutes at each titration step and 260 𝑔2 (𝒓, 𝜏) curves were
collected for each wavelength. The measurement duration for each autocorrelation
function at each wavelength was 1 second. Only 150 data points measured at each
wavelength and each step were used for data analysis, as the noisy data collected during
the periods of adding, stirring and dissolving ink were excluded. At the final step of the
titration (µa = 0.15 cm-1), the light intensity collected by the single-mode fiber (SM600)
reached a minimal value of ~10 kilo counts per second (kcps) that could barely be
detected by DCS.
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Figure 6.1: A fiber-optic probe consisting of two source fibers (S1 = 785 nm and S2 =
853 nm) and three detector fibers (D1 to D3). Multi-mode fiber (1mm) locates in D1,
single-mode fiber (SM600) locates in D2, and few-mode fiber (SM980) locates in D3. The
separations between the sources and detector fibers are equal (i.e., SD1 = SD2 = SD3 = 2.5
cm). The separations between detector fibers are D1D2 = 4.6 cm, D1D3 = 4.3 cm and D2D3
= 0.8 cm, respectively. Figure 27

For flow data analysis theoretical µa and µs’ from the phantom at each titration step
were used as inputs when fitting flow index DB (67). Relative changes in DB were
calculated by normalizing/dividing the time-course data to the mean values of the first
titration data. For the analysis of phantom absorption coefficient, µa (λ) at the first
titration step was assigned to be the theoretical value of the phantom (e.g., µa (853 nm) =
0.05 cm-1) and µa (λ) values at other titration steps were then calculated by adding the
corresponding ∆µa (λ) values measured by the DCS flow-oximeter. Standard deviations
of the measured variables were calculated and displayed as error bars along with the
mean values.

6.2.4 In vivo Tissue Measurements
The single-mode, few-mode and multi-mode fibers were further used to investigate
the SNRs in DCS flow-oximeter measurements on human tissues. The in vivo
experiments were approved by the University of Kentucky Institutional Review Board.
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Seven healthy subjects signed consent forms and participated in this study. Each subject
was asked to lay supine on a bed and extend his/her forearm. Prior to the DCS flowoximeter measurement the commercial tissue-oximeter Imagent with a hand-held probe
was used to obtain absolute baseline values of µa, µs’, [Hb] and [HbO2] in the
participant's forearm flexor carpi radialis muscle (71). The hand-held probe was removed
and the fiber-optic probe developed for this study (Figure 6.1) was taped on the same
location in forearm muscle to continuously monitor rBF, ∆[Hb] and ∆[HbO2] during 5minute arterial cuff occlusion. An optical attenuator was attached to the multi-mode
detector fiber to avoid saturating the highly sensitive APD. The forearm muscle went
through three different physiological stages during the cuff occlusion on upper arm: 5minute resting baseline, 5-minute cuff inflation (230 mmHg), and 5-minute recovery
following cuff deflation.
Similar to the phantom data analysis the baseline µa and µs’ measured by the Imagent
were used as inputs when fitting flow index αDB. Relative changes in αDB were
calculated by normalizing/dividing the time-course data to the mean values of the 5minute resting baselines. The [Hb] and [HbO2] were calculated by adding their baseline
values measured by the commercial Imagent and the corresponding ∆[Hb] and ∆[HbO2]
measured by the DCS flow-oximeter. To be consistent with the phantom data analysis
150 data points at each stage were used to calculate the corresponding SNRs. Standard
errors were calculated over the 7 subjects and plotted as error bars along with the mean
values in the figures.
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6.2.5 SNR Calculations
The variables measured by or derived from the DCS flow-oximeter include 𝑔2 (𝒓, 𝜏),
αDB/rBF, light intensity I, ∆µa, ∆[Hb] and ∆[HbO2]. SNR calculations for most of these
variables follow the conventional definition (140):

SNR 

MEAN ( signal )

(6.3)

STD (noise)

Here, “STD” represents standard deviation, “MEAN” represents mean value,
“signal” is the measured raw data, and “noise” is the high-frequency component of the
measured raw data. The high-frequency noises originate from electronics, optics,
positioning of the source and detectors, and physiological variations (only applicable to
in vivo measurements) (9). The electronic noises include shot noise, thermal noise and the
noise induced by the dark current of APD. The optic noises arise mainly from the fiber
modal noise and the loss/variation of higher order modes due to the fiber
bending/vibration. The physiological variations come from the respiration, heartbeat, and
subject’s movement.
The “noise” in Equation 6.3 for each set of measured raw data (150 data points) was
obtained using a first order Butterworth high-pass filter with a corner frequency of 0.05
Hz (83). This corner frequency was determined by analyzing the power spectral densities
(PSDs) of the measured hemodynamic signals from forearm muscles, and was selected to
be higher than the highest frequency (0.05 Hz) of the valid signals (i.e., slow
hemodynamic changes during cuff occlusion) but lower than the DCS sampling rate
(~0.4 Hz) and the highest frequency of noises. The MEAN (signal) may be equal to 0 for
some variables (e.g., rBF ≈ 0 during cuff occlusion), resulting in zero SNR. In this case
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the STD (noise) was used to evaluate measurement variability.
Unlike those variables (described above) depending only on time (t), 𝑔2 (𝒓, 𝜏)is a
function of delay time τ at each measurement time point (t). To calculate the SNR of
g 2 (r , ) at multiple τ, a previously established method is followed (83, 136):

SN (𝜏) =

MEAN(𝑔2 (𝒓,𝜏)−1)
STD(𝑔2 (𝒓,𝜏)−1)

(6.4)

The calculation was carried out among the 150 datasets of (𝑔2 (𝒓, 𝜏)-1). The MEAN
and STD of the 150 (𝑔2 (𝒓, 𝜏)-1) curves at each delay time τ were used to estimate SNR(τ)
according to Equation 6.4.
Differences among the three fibers in mean values of SNR or STD averaged over 7
subjects were tested using the SAS (Statistical Analysis System) Version 9.3 software
package and assessed by wavelength (only applicable to rBF) and during baseline, cuff
occlusion, and recovery stages. Normality of the mean differences over 7 subjects was
assessed using Shapiro-Wilks test (141). Any p-value less than 0.10 was considered to
result in a departure from normality of the mean difference and a Wilcoxon Signed-Rank
test (142) was used to assess whether the mean difference was significant in this case.
Where there was no departure from normality the paired t-test was used to assess
significance of the mean differences. A p-value of 0.05 was considered significant for the
mean differences examined in SNR or STD of rBF between the single-mode and fewmode fibers. A Bonferroni-corrected p-value of 0.017 (0.05/3) was considered significant
for the mean differences examined in SNRs or STDs of [Hb] and [HbO2] between any
two groups of single-mode, few-mode and multi-mode fibers.
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6.3 Results
6.3.1 Phantom Experimental Results
Flow Measurement. During the phantom titration experiments µa (853 nm) was
varied from 0.050 cm-1 to 0.150 cm-1 with a step size of 0.025 cm-1 while µs’ was kept
constant (8 cm-1) throughout all steps. Figure 6.2a shows typical 𝑔2 (𝒓, 𝜏) data (dots) and
fitting curves (solid lines) recorded at 785 nm and collected by the single-mode (SM600)
and few-mode (SM980) fibers. The data presented in Figure 6.2a were randomly
selected from ~150 𝑔2 (𝒓, 𝜏) curves over each titration step. As mentioned in Chapter
6.2.1, β and DB can be simultaneously derived by fitting the measured 𝑔2 (𝒓, 𝜏). In
addition, β can also be estimated based on the Siegert relation using the measured
𝑔2 (𝒓, 𝜏) data at earliest τ and letting the normalized autocorrelation function g1 ≈1, i.e.,
β = g 2 (  0) - 1. For example, the β values for the single-mode and few-mode fibers can
be estimated by the intercept values of fitted 𝑔2 (𝒓, 𝜏) curves, notated as A and B in
Figure 6.2a. For the first titration (Step 1), the β values calculated over 150
measurements were 0.46 ± 0.013 and 0.16 ± 0.013 for the single-mode (SM600) and fewmode (SM980) fibers, respectively. Correspondingly, 1/β values were approximately
equal to the numbers of guided modes of light (N): ~2 for the single-mode (SM600) fiber
and ~6 for the few-mode (SM980) fiber. These numbers agreed with the theoretical
values calculated based on fiber properties in Chapter 6.2.2. As µa increased the g 2 ( r ,  )
curves became noisier for both single-mode and few-mode fibers. However, the curves
collected by the few-mode fiber were always smoother than those recorded by the singlemode fiber over the titration steps (Figure 6.2a). To further quantify the performance of
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the two fibers we calculated the SNRs over 150 𝑔2 (𝒓, 𝜏) curves at each delay time τ for
all titration steps using the method described in Chapter 6.2.5. Results shown in Figure
6.2b indicated that the SNRs of 𝑔2 (𝒓, 𝜏) detected by the few-mode fiber were slightly
higher than the single-mode fiber, which appeared more obvious at the early decay time τ.
Similar results were found at the wavelength of 853 nm (data are not shown).

Figure 6.2: (a) Typical 𝑔2 (𝒓, 𝜏) data (dots) and fitting curves (solid lines) recorded at
785 nm and collected by the single-mode (SM600) and few-mode (SM980) fibers at five
titration steps. The 𝑔2 (𝒓, 𝜏) curves are randomly selected at a single measurement time
point t over 5 steps. The intercepts (e.g., A and B at Step 2) can be used to estimate β
values (i.e., β = intercept value -1), which are the inverse of guided mode numbers (~2
for SM600 and ~6 for SM980). (b) Corresponding SNRs calculated from the 150
𝑔2 (𝒓, 𝜏) curves at each titration step. Figure 28

The relative flow data (normalized DB) at five titration steps are shown in Figure 6.3a.
Vertical lines separate different titration steps. Since multiple uncorrelated speckle
fluctuations were collected by the multi-mode fiber (1mm) the measured autocorrelation
function curve 𝑔2 (𝒓, 𝜏) became completely flat (a straight line) which cannot be fit using
the algorithm described in Chapter 2.3. Therefore, only flow data (150 data points)
collected by the single-mode and few-mode fibers were reported. As µa increased relative
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flow data recorded at two wavelengths became noisier for both single-mode and fewmode fibers, but the signal fluctuation observed when using the few-mode fiber was less
than using the single-mode fiber. The difference in flow variations between the two fibers
can be seen more clearly from Figure 6.3b where the STDs of noises are illustrated as
error bars. Notice that flow increased slightly with the progress of titration which was
likely due to the fitting errors at the titration steps with higher μa values associated with
higher noises (83). Figure 6.3c shows the SNRs of relative flow at five titration steps
calculated using Equation 6.3. The SNRs for both single-mode and few-mode fibers
decreased as µa increased, and the few-mode fiber achieved slightly higher SNRs than the
single-mode fiber. These results are consistent with the findings shown in Figures 6.3a
and 6.3b.

Figure 6.3: (a) Measured relative flow (normalized DB) during the phantom titration
experiment detected by the single-mode (SM600) and few-mode (SM980) fibers at the
two wavelengths (785 and 853 nm). (b) Mean values of relative flow and standard
deviations of noise (error bars). (c) Corresponding SNRs of relative flow at the two
wavelengths and five titration steps. Figure 29
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Optical Property Measurements. Figure 6.4a displays the light intensities at two
wavelengths collected by the three fibers during titrations. As expected, higher mode
fibers collected more photons. Figure 6.4b shows the mean values of light intensities and
STDs of noises (error bars) at five titration steps. In order to clearly show the error bars
they were multiplied by a factor of 100. It can be observed from Figure 6.4b that with
the increase of light intensity both MEAN (signal) and STD (noise) increased. The noise
level increased because the higher light intensity increased shot noises from the photon
detectors and random noises generated by photons transporting through the medium.
Nevertheless, the increase of MEAN (signal) was larger than the increase of STD (noise).
As a result, the SNR increased with the increase of light intensity (Figure 6.4c). The
SNRs tended to decrease with the increase of μa, although such decreases were not
remarkable at the early titration steps where the light intensities and SNRs were relatively
high.
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Figure 6.4: (a) Measured light intensities at the two wavelengths (785 and 853 nm)
collected by the single-mode (SM600), few-mode (SM980) and multi-mode (1mm) fibers
during the phantom titration experiment. The light intensity unit of “kcps” stands for kilo
counts per second. (b) Averaged light intensities and standard deviations of noise (error
bars) at the two wavelengths. The standard deviations of noise are multiplied by a factor
of 100 to clearly display the error bars. (c) Corresponding SNRs of light intensities at the
two wavelengths and five titration steps. Figure 30

The retrieved µa values at five titration steps and two wavelengths using the three
fibers with different modes are displayed in Figure 6.5a. The µa (λ) value at the first
titration step was assigned to be the theoretical value of the phantom (i.e., µa = 0.05 cm-1
at the wavelength of 853 nm). Figure 6.5b shows the mean values of μa and STDs of
noises at five steps and two wavelengths. Again, in order to clearly show the error bars
they were multiplied by a factor of 100. Horizontal dashed lines displayed in Figures
6.5a and 6.5b indicate the theoretical μa values of the phantom at each step. All three
fibers were able to extract µa with relatively small errors. The measurement error in μa
was estimated by the percentage difference between the measured and theoretical values.
The maximum measurement errors from the few-mode (1.6% at 785 nm and 1.3% at 853
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nm) and multi-mode (4.3% at 785 nm and 4.8% at 853 nm) fibers were much smaller
than those from the single-mode fiber (6.3% at 785 nm and 11% at 853 nm). Although
differences in measurement error existed between the few-mode (≤ 1.6%) and multimode (≤ 4.8%) fibers, the measurement errors (< 5%) from both fibers were comparable
with previous NIRS results (< 6%) using multi-mode fibers (67, 71). The STDs of
measurement noises (error bars) increased with the increase of µa and the decrease of
fiber mode number. The SNRs of µa at the five steps and two wavelengths are displayed
in Figure 6.5c. It is clear that higher SNRs for µa can be achieved by increasing the
number of optical fiber modes.

Figure 6.5: (a) Measured µa values at the two wavelengths (785 and 853 nm) collected
by the single-mode (SM600), few-mode (SM980) and multi-mode (1mm) fibers during
the phantom titration experiment. The horizontal dashed lines indicate theoretical µa
values of the phantom at each step. (b) Averaged µa values and standard deviations of
noise (error bars) at the two wavelengths. The standard deviations of noise are multiplied
by a factor of 100 to clearly display the error bars. (c) Corresponding SNRs of µa values
at the two wavelengths and five titration steps. Figure 31
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6.3.2 In vivo Tissue Measurement Results
rBF Measurements. Figure 6.6a shows typical rBF data at 785 and 853 nm
collected by the single-mode and few-mode fibers during 5-minute arterial cuff occlusion
from one subject. Similar to phantom measurements the measured 𝑔2 (𝒓, 𝜏)

curve

collected by the multi-mode fiber (1mm) was a straight line which cannot be used to
extract blood flow information. The raw rBF data (150 data points at each stage) were
processed by the high-pass filter with a corner frequency of 0.05 Hz to extract the noises
(Figure 6.6b). Vertical lines in Figures 6.6a and 6.6b separate different stages of
occlusion (i.e., baseline, occlusion, recovery). The mean SNRs and standard errors (error
bars) over 7 subjects at the baseline and recovery stages are displayed in Figure 6.6c.
The SNRs of rBF at the occlusion stage were equal to zero and thus not reported. Instead,
the STDs of rBF noises and their variations (standard errors shown as error bars) over 7
subjects at all three stages are shown in Figure 6.6d. Assessed by SAS software (see
Chapter 6.2.5), the p-values from the paired t-test/Wilcoxon Signed-Rank tests were
larger than 0.222 indicating that the mean differences in SNR/STD of rBF over 7 subjects
between the single-mode and few-mode fibers were not significant at all three stages of
cuff occlusion.
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Figure 6.6: (a) Typical forearm muscle rBF responses during 5-minute arterial cuff
occlusion collected from one subject using the single-mode (SM600) and few-mode
(SM980) fibers. (b) rBF noise processed by the high-pass filter with a corner frequency
of 0.05 Hz. (c) Averaged SNRs of rBF and corresponding standard errors (error bars) of
noise at baseline and recovery stages over 7 subjects. (d) Averaged standard deviations of
high-frequency noises and corresponding standard errors (error bars) at baseline, cuff
occlusion, and recovery stages over 7 subjects. Figure 32

Oxygenation Measurements. Figure 6.7a displays the [Hb] and [HbO2] data during
5-minute arterial occlusion measured by the three fibers with different modes from the
same subject shown in Figure 6.6. Apparently, [Hb] and [HbO2] curves became
smoother (Figure 6.7a) and noises were less (Figure 6.7b) when using higher mode
fibers. Figure 6.7c displays the mean SNRs and their standard errors (error bars) over 7
subjects. Assessed by SAS software (see Chapter 6.2.5), the p-values from the paired ttest/Wilcoxon Signed-Rank tests were smaller than 0.016 when evaluating the
significance between the few-mode and single-mode fibers and between the multi-mode
and single-mode fibers. As noted in Chapter 6.2.5 a Bonferroni-corrected p-value of <
0.017 was considered significant. This result indicated that the mean SNRs of both [Hb]
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and [HbO2] using the few-mode and multi-mode fibers were significantly higher than
those using the single-mode fiber.

Figure 6.7: (a) Typical [Hb] and [HbO2] responses during 5-minute arterial cuff
occlusion collected from the same subject shown in Figure 6.6 using the single- (SM600),
few- (SM980) and multi-mode (1mm) fibers. (b) [Hb] and [HbO2] noises processed by
the high-pass filter with a corner frequency of 0.05 Hz. (c) Averaged SNRs of [Hb] and
[HbO2] and corresponding standard errors (error bars) of noises at baseline, cuff
occlusion, and recovery stages over 7 subjects. Figure 33

6.4 Discussion and Conclusions
Traditional NIRS can measure tissue optical properties including μa, μs’, [Hb] and
[HbO2] while the emerging DCS can measure rBF in deep tissues. By combining these
two technologies to form a hybrid instrument, rBF, [Hb] and [HbO2] can be obtained
simultaneously (55, 66). Consequently, relative changes in tissue oxygen metabolism can
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be derived using simple models (55, 59, 66). While the hybrid instruments (NIRS + DCS)
can be used to measure multiple hemodynamic/metabolic parameters providing deeper
insights about tissue physiological status than one parameter alone, they are relatively
large, complex and expensive. The dual-wavelength DCS flow-oximeter is an emerging
technique enabling simultaneous measurements of tissue blood flow and oxygenation
changes (41, 46, 67, 78, 127). Being noninvasive, fast, relatively inexpensive and truly
portable (dimensions: 8”× 12”×18”), DCS flow-oximeter is suitable for bedside
monitoring in the clinics. Furthermore, the new probe designed for the DCS flowoximeter shares source and detector fibers for both flow and oxygenation measurements.
Therefore, it covers exactly the same tissue volume and avoids any discrepancies
between the blood flow and oxygenation measurements owing to the tissue heterogeneity.
For clinical measurements large light penetration is needed to probe optical properties
in deep tissues (e.g., adult brain and muscle). According to photon diffusion theory a
given source-detector (S-D) pair is mostly sensitive to the area at a depth of 1/3 to 1/2 of
the S-D separation (45, 65, 67, 143). However, the larger the S-D separation the weaker
the signal detected. Improving SNR is especially crucial when the detected signal is
extremely low which is not unusual for DCS measurements in human tissues (40, 41, 54,
75-78).
According to Equation 6.3, SNR can be improved by increasing the light intensity
injected into the tissue which is, however, not unlimited and has to be controlled to meet
ANSI (American National Standards Institute) standards for laser safety usage. An
alternative method is to use a low-pass filter to reduce the high frequency noises, but this
may not be possible when the bandwidths of signal and noise are overlapped. This study
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was designed to investigate the possibility of using the few-mode or multi-mode
detection fibers instead of the single-mode fiber to increase the light intensity detected
and thus improve SNRs of DCS flow-oximeter measurements. The rationale behind this
hypothesis is that few-mode or multi-mode fibers allow higher order modes of light to be
guided through along with the fundamental single mode which would increase the light
intensity detected (135).
To test the hypothesis the single-mode (SM600), few-mode (SM980) and multi-mode
(1mm) fibers were examined in tissue-like liquid phantoms with varied optical properties
and in forearm muscles during arterial cuff occlusion. The liquid phantom provided a
homogeneous tissue model without the interference of physiological variations that exist
in biological tissues (41, 67, 92), while the use of human muscles allowed for the
evaluation of fiber performance in real tissues (39, 76, 77, 127, 128).
The results obtained from the phantom titration experiments indicated that the fewmode fiber slightly improved the SNRs of relative flow measurements compared to the
single-mode fiber used (see Figure 6.3c). Although the slight SNR improvement in flow
measurements was somewhat disappointing it was not surprising because the few-mode
fiber with larger diameter and numerical aperture increased the detected signal intensity
(see Figures 6.4a and 6.4b) but decreased the coherence factor β in a proportional
fashion (see Figure 6.2a). A smaller β corresponded with a flatter autocorrelation
function curve leading to a lower sensitivity of DCS flow measurements (60, 136).
Therefore, the SNR of autocorrelation function, depending on both light intensity
detected and coherence factor β (136), may not be highly improved (see Figure 6.2b).
Although the detected light intensity can be further increased by using the multi-mode
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fiber with a large diameter of 1 mm (see Figures 6.4a and 6.4b) the autocorrelation
function was not detectable in this case due to the very low value of β. Furthermore, the
SNR improvements were not obvious during in vivo rBF measurements in forearm
muscles (see Figures 6.6c and 6.6d). Unlike phantom experiments in vivo measurements
could be influenced by many factors such as physiological variations, motion artifacts,
fiber-tissue coupling coefficient and tissue heterogeneity which could impact the
measurements differently on different fibers (39, 54, 124, 128). Such in vivo “noises”
may bury the slight SNR improvements of flow measurements observed in phantom
experiments.
In contrast to flow measurements, significant SNR improvements were achieved
when using the few-mode or multi-mode fiber (versus single-mode fiber) in both
phantom measurements of light intensity (see Figures 6.4c) and μa (see Figures 6.5c)
and in in vivo measurements of [Hb] and [HbO2] (see Figures 6.7c). The significant SNR
improvements for these variables were expected as they all depended on the light
intensities detected which were highly different among the three fibers (see Figures 6.4a
and 6.4b). The larger the number of optical fiber mode the higher the detected light
intensity.
The level of the detected light intensity also greatly impacted SNRs of the measured
variables at different titration steps and different physiological stages. For example, with
the increase of μa during the phantom titration the detected light intensity decreased step
by step leading to a continual decrease in SNRs for all three fibers and two wavelengths
(see Figures 6.3 and 6.4). One exception is the derived value of μa during phantom
experiments where the SNRs of μa at the first titration step for both wavelengths were
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lower than those at other steps (see Figures 6.5c), although the light intensities detected
at the first step were higher (see Figures 6.4a and 6.4b). Since the μa values at the first
titration step were much smaller than those at other steps (e.g., ~1.5 times smaller than
the second step) but the STDs of μa at all steps didn’t vary much, it was not surprising
that the SNRs of μa at the first titration step for both wavelengths were smaller than those
at other steps according to Equation 6.3. Furthermore, the SNRs of [Hb] and [HbO2]
during the cuff occlusion stage were lower than those at baseline and recovery stages for
all three fibers (see Figure 6.7c) which was again due to the lower light intensities
detected during occlusion compared to other two stages. In addition, the light intensity
detected from the wavelength of 853 nm was ~2 times lower than the 785 nm wavelength
(see Figures 6.4a and 6.4b) resulting in lower SNRs for the 853 nm wavelength at most
titration steps and physiological stages (see Figures 6.3 to 6.6), although laser stability
could also impact the SNRs.
Besides the SNR improvements the few-mode and multi-mode fibers measured the
optical property μa more accurately than the single-mode fiber (see Figures 6.5a and
6.5b). Smaller measurement error represented higher measurement accuracy. The
measurement errors in μa from the few-mode and multi-mode fibers were < 5% for both
wavelengths (Figure 6.5a) which were comparable with those (< 6%) observed in
previous studies using NIRS with multi-mode fibers (67, 71). The maximum errors from
the single-mode fiber (< 11%) were much larger than those from the other two fibers
(<5%) (Figure 6.5a) and those reported in literature (< 6%), which was again due to less
light intensities collected (associated with higher noises) by the single-mode fiber.
In conclusion, the experiments in this chapter demonstrated the advantages of using
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the few-mode fiber for DCS flow-oximeter measurements of both blood flow and
oxygenation compared to using the single-mode fiber. The few-mode fiber enabled
collection of more photons from the phantoms/tissues resulting in higher SNRs in both
flow and oxygenation measurements, although the SNR improvements with the fewmode fiber were found to be significant only in oxygenation measurements. The multimode fiber can further increase the detected light intensities and SNRs for tissue
oxygenation measurements, but the autocorrelation functions for extracting flow
information cannot be detected due to the very low value of β.
Based on these results, selection of fibers with certain modes may depend on the
particular application. For the measurements of blood flow only either single-mode fiber
or few-mode fiber can be used, although the few-mode fiber may generate slightly higher
SNRs of flow data. For simultaneous measurements of tissue blood flow and oxygenation
using the dual-wavelength DCS flow-oximeter, a few-mode fiber (instead of single-mode
fiber) should be used to obtain significantly higher SNRs of tissue oxygenation
measurements. An alternative way is to use a detection fiber bundle consisting of one
single-mode (or few-mode) fiber and one multi-mode fiber. The single-mode or fewmode fiber can measure autocorrelation functions to extract flow information while the
multi-mode fiber can detect light intensities at the two wavelengths with significantly
higher SNRs (than both single-mode and few-mode fibers) to extract oxygenation
information. However, the latter option requires two detectors connected to the fiber
bundle which would increase the instrumentation costs.
This pilot study was limited to comparing the SNRs of DCS flow-oximeter
measurements among three types of fibers (i.e., single-mode, few-mode, multi-mode).
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The selection of these specific three fibers was mainly based on fiber availability. The
optimization of fiber modes used for achieving optimum SNRs in tissue hemodynamic
measurements may be the subject of future study.
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CHAPTER 7 STUDY SUMMARY, LIMITATIONS, AND FUTURE
PERSPECTIVES

7.1 Study Summary
In this dissertation, I reported the development and application of ncDCT system for
3-D blood flow imaging in human breast tumors. The imaging system utilized lens
focusing apparatus to project source and detector fibers onto tissue surface. A motorized
stage was integrated into the system for automated and customizable ROI scanning
around tumor bearing region. A commercial 3-D camera was used to obtain breast
surface geometry which was then converted to a solid volume mesh. Furthermore, a finite
element framework was integrated to our DCT imaging algorithm which enabled blood
flow imaging with arbitrary tissue geometry. System validation work including computer
simulations and phantom experiments were performed to demonstrate the imaging ability
of the ncDCT system for breast tumor detection. I also reported our first step to adapt the
ncDCT system for tumor-to-normal blood flow contrast imaging from patients with
breast tumors. In addition to this primary study, an optical fiber study was conducted to
improve the SNR of DCS flow-oximeter measurement. The results reported in this
dissertation have been presented in conferences and some of them have been published in
peer-reviewed journals (see my attached CV).
My major contributions in these studies include the following aspects:
First, I developed the imaging algorithms for ncDCT of breast tumor blood flow
contrasts (Chapter 2) (37, 144). I designed computer simulations and conducted
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phantom experiments to validate and optimize the algorithms and the ncDCT system
(Chapters 3 and 4).
Second, I participated in the design and construction of noncontact DCS/DCT system
(Chapter 3) (37, 89, 92). I first involved in the design of a noncontact DCS (ncDCS)
probe with single S-D separation. I designed and performed phantom and human tissue
experiments to test the ncDCS probe. When extended the ncDCS to ncDCT, I further
performed computer simulations to optimize the source and detector arrangement, and the
scanning protocol for boundary data collection. To generate breast-shaped mesh, I
utilized different commercial software (i.e., ScanStudio, Ansys and SolidWorks) to
convert breast surface geometry, taken by a 3-D camera, to solid volume mesh for
ncDCT image reconstruction.
Third, for the first time I applied the ncDCT system on clinical breast tumor study
(Chapter 5) (144). I recruited 28 patients with breast tumors and performed optical
measurements. I was able to reconstruct 3-D images of tumor blood flow distributions
inside breasts and the majority of reconstructed images showed higher blood flow
contrasts in the tumor regions compared to the surrounding normal tissues. Reconstructed
tumor depths and dimensions matched ultrasound imaging results when the tumors were
within the sensitive region of light propagation. The results demonstrated that ncDCT
system has the potential to image blood distributions in soft and vulnerable tissues
without distorting tissue hemodynamics.
Last, in order to improve the SNR of DCS flow-oximeter measurements, I
experimentally explored using different detector fibers with different modes (i.e., singlemode, few-mode, multimode) for photon collections (Chapter 6) (129). The outcomes
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from this study provided useful guidance for the selection of optical fibers to improve
DCS flow-oximeter measurements.

7.2 Study Limitation and Future Perspectives
Tumor Location Recovery. The ncDCT imaging results from computer simulations
and in vivo breast tumor measurements suggest that reconstructed tumor depths and
dimensions are accurate when the anomaly/tumor was within the sensitive depth of
diffuse light. When the tumor locates deeper than the maximal light penetration depth,
lower part of the tumor cannot be sampled by the ncDCT probe (Figure 2.1a).
Consequently, the reconstructed tumor location may be shifted up. Depth correction
algorithms should be considered for the imaging process for improvement (106, 107);
more weights may be added to elements located deep in the volume mesh when
calculating the Jacobian matrix. On the other hand, prior knowledge of tumor location
and dimension can also improve the recovery of tumor flow contrasts and locations using
anatomical imaging modalities such as MRI or CT. It should be noted that ncDCT
cannot detect tumors located deeper than diffuse lights can reach.
Tumor Flow Contrast Recovery. Even though the ncDCT system can detect the
majority of breast tumors measured, we were unable to differentiate between malignant
and benign tumors with the detected blood flow contrasts. This might be due to the
overlap of blood flow contrast in different stages of malignant tumors and different types
of benign lesions. Crosstalk between 𝜇𝑎 , 𝜇𝑠′ and BFI may also result in over- or underestimation of blood flow contrasts in ncDCT (67, 83). To overcome this limitation, a
separate instrument enabling 3-D imaging of 𝜇𝑎 and 𝜇𝑠′ distributions of breast tissue is
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needed (e.g., a frequency-domain or time-resolved DOT (32, 120-122)). We can also
increase the valid boundary measurement pairs by updating our line-shaped sources and
detectors arrangement to 2-D array, so that the ill-posed inverse problem could be
reduced to improve the flow contrast reconstruction accuracy.
Clinical Limitations and Improvements. Current measurement protocol takes ~40
minutes for each individual measurement. However, sometimes patients may move
during the measurement, leading to motion artifacts or even the discontinuity of data
collection. In the future, ncDCT measurement time should be reduced. The 2-D array of
sources and detectors arrangement mentioned earlier can avoid the scanning procedure
and thus avoiding such influence (145).
It is expected that with further instrument and algorithm development and more
clinical applications in large patient population, our ncDCT system may emerge as an
alternative functional imaging modality to help detect/characterize different kinds of
breast tumors. Furthermore, ncDCT can be used for other applications such wound tissue
and pressure ulcer without distorting hemodynamic properties.
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APPENDIX: GLOSSARY
SYMBOLS
α

Ratio of Dynamic to Static Scatterers (0-1)

D

Photon Diffusion Constant

DB

Effective Diffusion Coefficient

g1

Normalized Electric Field Temporal Autocorrelation Function

G1

Unnormalized Electric Field Temporal Autocorrelation Function

g2

Normalized Intensity Temporal Autocorrelation Function

I

Intensity

k0

Wavevector of Photons in Medium (k0 = 2πn/λ)

λ

Wavelength

n

Ratio of Sample and Air Index of Refraction

NA

Numerical Aperture

φ

Phase Modulation of NIR Light

ρ

Source-detector Separation

r

Position Vector

<Δr2(τ)>

Mean-square Displacement of Scatterers during τ

S0

Source-light Distribution

Φ

Photon Fluence Rate

τ

Correlation Function Delay Time

𝜏1

Selected Delay Time for DCT Image Reconstruction

µs’

Reduced Scattering Coefficient

µa

Static Absorption Coefficient
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𝜇𝑎𝑑

Effective Dynamic Absorption

𝜇𝑎𝑡𝑜𝑡𝑎𝑙

Total Absorption Coefficient

ν

Speed of Light in Medium

V

Fiber Normalized Frequency

VC

Fiber Cutoff Frequency

[x]

Concentration of x

ω

Angular Frequency of Modulation

β

Coherence Factor

λC

Fiber Cutoff Wavelength

TERMS
APD

Avalanche Photodiode

BFI

Blood Flow Index (αDB)

CW

Continuous Wave

CT

Computed Tomogaphy

𝐶𝑣

Coefficient of Variation

DCS

Diffuse Correlation Spectroscopy

(nc)DCT

(noncontact) Diffuse Correlation Tomography

DWS

Diffusing Wave Spectroscopy

FD

Frequency Domain

FWHM

Full Width Half-maximum

Hb

Deoxy-hemoglobin

HbO2

Oxy-hemoglobin
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J

Jacobian Matrix

NIR

Near-Infrared

NIRS

Near-Infrared Spectroscopy

PET

Positron Emission Tomography

RBC

Red Blood Cell

rBF

Relative Blood Flow

S-D

Source-Detector

SNR

Signal to Noise Ratio

StO2

Tissue Oxygen Saturation

TD

Time Domain

tHb

Total Hemoglobin
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